drug research develop activ key activ research develop phase creat new drug
anti anemia drug final get close circul
magic potion clear liquid pack vial kept refriger thou oak warehous sit wait sold
latest biotechnolog drug call erythropoietin epo anti anemia treatment seven year million research develop first commerci product compani call amgen
said gordon binder amgen chief execut
amgen new manufactur plant run ha turn three month suppli epo amgen hire salespeopl ha line refriger warehous around countri keep drug fresh
everi thing readi save one thing
food drug administr approv sell drug
one expect fda reject amgen request sell epo hormon trigger product red blood cell clinic test success fulli treat chronic anemia suffer patient kidney diseas
epo wa discov scientist bodi produc onli microscop amount hormon challeng ha get enough
abl make drug biotechnolog scientist medic detect resplic gene carri blueprint life trigger product rare hormon protein use therapeut drug
amgen ha submit page support document conduct extens epo test patient win glow review new england journal medicin
amgen execut hope fda would complet elabor review approv epo sale late
compani veri optimist drug approv sale march binder said
dure wait amgen stock ha bounc scrap news fda approv process
financi analyst still expect amgen first compani win approv sell epo becaus appli fda year ahead ani compani
unnerv though one seem certain plenti rich
novemb amgen stock spurt analyst shearson lehman hutton predict worldwid sale epo
excit amgen last week mont gomeri secur analyst denis gilbert made project epo would sell million unit state stock dip
troubl stock market ha lost much confid biotechnolog fear onli compani hundr actual produc drug big winner
compani ha five drug undergo test human epo ha secur littl compani reput boost valu amgen stock million even though essenti ha without product sell
sale primarili advanc compani research develop partner profit invest
stock market also pessimist biotechnolog becaus mani misadventur genentech san francisco biotech compani whose reput took terribl beat last year
year ago genentech stock wa trade per share wa end enthusiasm latest drug tpa anti blood clot agent could save heart attack victim
drug would sell million first year analyst boast genentech execut noth discourag expect
genentech end sell million worth tpa still record first year sale new drug stock collaps languish
drug wa expens dose tpa time price older heart attack drug variou studi inconclus tpa advantag drug
onli last month genentech wrote million worth tpa inventori becaus drug perish sale far slower compani optimist project
gilbert recent trim profit estim amgen compani execut told would need spend get epo market
still analyst figur amgen ha big winner epo
biggest use help treat patient undergo kidney dialysi cleans impur blood
patient cannot produc enough red blood cell mani need transfus four quart blood month
patient inject epo need transfus abl go live normal
encourag compani come drug treat rel rare diseas congress award call orphan drug statu seven year exclus franchis first manufactur drug
epo qualifi orphan drug amgen ha shrewdli kept right sell epo kidney dialysi patient
jim mccamant editor medic technolog stock letter say like million year market thi countri
possibl use epo may also work treat kind anemia includ chemotherapi leukemia patient
epo also test zt aid treatment drug produc anemia side effect
sale epo patient kidney diseas would open compani version epo analyst agre big market
johnson johnson sell amgen version epo dispar use thi countri pay amgen royalti estim analyst gross sale
gilbert reckon amgen profit grow like weed million march fiscal year million
figur amgen second drug g csf produc white blood cell strike gold well
even amgen win epo race laboratori marketplac must still win battl wit courtroom ensur profit
amgen lock four patent infring lawsuit chief rival genet institut biotech compani chugai pharmaceut tokyo race get version epo approv sale unit state
analyst figur genet institut headquart cambridg mass
amgen genet institut separ seemingli conflict patent relat epo could take year case go way u
case resolv compani free sell new drug whichev compani win court figur take home biggest share profit
genet institut ha discuss court settlement amgen presum sort cross licens deal could sell drug amgen execut refus
isi founder troubl l ure backer unexplor frontier biotechnolog
isi pharmaceut presid stanley crook walk hi compani newli leas carlsbad facil took pain point despit mostli vacant offic laboratori space hi new biotechnolog firm hard work develop product temporari lab sorrento valley
nearli empti build carlsbad research center symbol crook formid task build compani scratch pioneer unexplor frontier biotechnolog translat yet undevelop technolog market product
crook form isi two month ago illustri career head product research oper two jor pharmaceut firm smith kline beckman bristol myer
crook hold medic degre well doctor pharmacolog oversaw introduct new drug dure hi year two firm
cheaper boston select san diego counti isi headquart could near grow biotechnolog commun cluster around uc san diego scripp clinic research foundat
although hous expens san diego crook said cheaper boston san francisco bay area two headquart site consid
carlsbad wa chosen counti locat becaus favor leas rate said
said christoph gabri gener partner bessem ventur partner menlo park base ventur capit firm invest eight biotechnolog compani includ isi
describ drug develop enorm complex drawn expens process
befor resign last summer crook wa vice presid charg smith kline research develop oper million budget
bristol myer left join smith kline crook help develop array chemotherapi drug cancer patient put bristol forefront cancer treatment
trade hi visibl pharmaceut industri crook ha move fast sinc start isi march
million ventur capit hire employe mani research star strong track record pharmaceut academia
crook wa abl rais money five ventur capit firm includ bessem plu obtain commit million next year even though isi may year away success ful technolog much less u
compani payrol grow employe year end mani said
said ray dittamor manag partner arthur young co
firm whose client includ quarter san diego biotechnolog compani includ isi
apart crook ventur capitalist interest revolv around technolog isi tri develop call anti sens oligonucleotid
oligo bit dna bind messeng molecul sent dna caus product diseas bear protein
bind diseas messeng call messeng rna oligo theoret prevent diseas messag pass thu ever produc crook said
said ignacio tinoco professor chemistri univers california berkeley isi scientif advisori board
crook said potenti anti sens drug enorm becaus could manufactur therapeut agent virtual ani diseas sinc virtual diseas start aberr protein set motion messeng rna molecul
isi plan develop anti sens drug use call ration drug design comput aid process design drug forc thought crook said
billion market cite competit concern crook refus disclos diseas isi ha target first set product
say howev compani pursu declin say whether aid one diseas target
isi competit far includ san diego base genta compani wa spun recent gen probe publicli held manufactur dna probe diagnost product
genta presid thoma adam wa unavail comment friday
crook said expect jor pharmaceut firm join field come year well
although crook studi anti sens oligonucleotid better part two decad said becam convinc could use therapeut drug three year ago
convict sprang advanc molecular biolog research enabl scientist clone synthes dna molecul
crook wa also encourag scientist increas abil modifi manipul molecul process call hybrid bind one molecul anoth
bind process isi anti sens nucleotid someday kill diseas caus rna molecul said
crook said wa unabl gener much enthusiasm among hi smith kline colleagu pursu technolog perhap becaus approach wa revolutionari
combin smith kline financi problem last year result impact scientist research program upper merion pa
return academia first crook plan leav drug compani wa return academia specif baylor colleg medicin houston ha faculti member past year
crook soon realiz wa enamor high stake game produc new drug social benefit success ful drug repres
turn point hi medic career came young doctor houston watch year old man die testicular cancer diseas larg curabl drug develop bristol myer dure crook tenur
march isi sign agreement appli biosystem publicli held biotech compani foster citi lead manufactur instrument produc dna
deal call two compani share right product develop
isi expect appli biosystem help surmount formid problem
produc anti sens drug adequ quantiti
produc dna deriv exceedingli difficult anyth trace amount said
said timothi geiser senior scientist appli biosystem
becaus difficulti product develop isi appli biosystem instead deriv substitut call dna analog
geiser said hi compani expect sign similar agreement anti sens manufactur
gene splice anemia drug okd sale
genet engin drug expect reliev chronic anemia suffer thou peopl kidney diseas wa approv sale thursday u
drug also ha shown promis treat anemia aid cancer patient wa yet approv use govern
announc cap eight year effort amgen inc
thou oak bring market expect one biotechnolog first blockbust drug
amgen costli drug known erythropoietin epo gene splice version natur occur protein kidney trigger product red blood cell turn transport oxygen throughout bodi
patient suffer kidney diseas produc enough red blood cell often veri littl energi mani must endur frequent blood transfus
kidney dialysi patient thi countri need frequent transfus ideal candid epo expert say
clinic test patient given inject epo longer need blood transfus found much old energi return
epo test aid drug zt hope minim anemia review treat type anemia suffer patient cancer rheumatoid arthriti diseas
said david weber secur analyst brokerag firm alex
fda approv epo sold brand name epogen onli anemia caus kidney diseas
howev onc market doctor may prescrib anemia due caus although practic ha note endors fda
could becom one expens drug ever reimburs feder govern eventu cost perhap million million year overal kidney dialysi patient
govern cost averag patient suffer kidney diseas would need worth drug everi year gordon binder amgen chief execut said expect feder govern cover expens
epo approv use howev determin much cost would pick case
pete stark oakland chairman health subcommitte hous way mean committe said concern hundr million dollar use epo could cost feder govern
concern may stem fact member stark staff use data releas court battl amgen anoth manufactur calcul would cost onli onli manufactur year suppli drug averag patient
amgen offici said high price charg drug would help compani recoup cost develop epo estim million would provid money develop new product
besid amgen winner fda approv patient wait get drug
amgen expect start sell epo last winter thing delay frustrat kidney dialysi patient began buy epo mail order europ
patient valeri buhler pasadena take advantag obscur fda polici allow person import drug legal avail oversea long purchas small amount person use
sinc march buhler ha spend month pocket buy epo pharmaci west germani
befor began twice week treatment said
sinc ad fda approv said wa fantast time well
kidney diseas patient lack natur protein would take regular inject drug life prevent anemia
keat director northern ohio red cross blood servic chairman fda advisori committe recommend drug approv
first compani win approv sell epo amgen expect win big chunk market kidney dialysi patient expect least million year earli
altern epo fact ha excit financi commun
drug amgen first commerci product compani said denis gilbert biotechnolog analyst mont gomeri secur
binder said first shipment drug market trade name epogen arriv next week doctor offic
end year binder expect amgen sell epo rate million year
amgen stock trade counter close thursday share
amgen ha kept right sell epo kidney dialysi market ha licens use drug thi countri johnson johnson
much busi amgen enjoy unclear becaus compani lock jor patent infring lawsuit epo biotech rival genet institut cambridg mass
amgen genet institut hold differ patent relat epo patent infring trial schedul begin aug
patent trademark offic begin hear thi summer decid two rival compani epo claim prioriti
past amgen offici refus consid court cross licens agreement genet institut tactic analyst say riski
binder said thursday howev court agreement alway possibl
possibl settlement bruce eisen chief patent counsel genet institut also said court pact possibl befor patent trial begin
fda award call orphan drug statu amgen epo ordinarili would give compani seven year exclus right sell drug kidney dialysi patient
orphan drug statu cover drug treat patient suffer rel rare diseas fewer case
fda also said might also award orphan drug statu anoth version epo ha develop chugai upjohn use technolog licens genet institut
joseph sobota chief oper offic chugai upjohn said hi compani hope win fda approv within six month expect vigor competitor despit amgen head start
amgen binder said spend heavili prepar launch drug amgen lost million fiscal year end march
howev analyst gilbert expect amgen pre tax earn million epo sale
ft jan survey world industri review
path follow last year world chemic pharmaceut industri diverg markedli spite common scientif base
buoy age popul increasingli expens sophist drug pharmaceut group prove inocul insidi slow world economi
contrast chemic sector ha confirm lament reput cyclic industri
industri make littl money make much pollut
recess gulf war batter demand basic chemic
time capac order boom time late even least effici plant profit continu come stream increas competit still
consequ squeez margin ha exacerb increas capit cost requir ever tougher environment legisl
compli environment legisl cut deepli ordinari capit expenditur
increas public legisl demand environment protect appear unlik slacken come year
end last year german chemic compani complain new tax emiss would stretch industri limit make germani expens manufactur certain type product
uk chemic industri associ estim capit expenditur environ doubl pound year pound
cost capac rise demand fall descent profit loss ha precipit
even german giant hitherto protect german reunif suffer slow
mr wolfgang hilger presid german chemic industri associ warn thi month german domest market wa like stagnat thi year wa sign upturn export market
onli far east ha demand held capac particularli petrochem sector look set grow rapidli next year invest newli industrialis nation come stream
drug prove panacea compani tri escap roller coaster ride cyclic commod chemic busi
ici rhone poulenc two group tradit involv basic chemic report profit last year heavili depend upon success pharmaceut busi
pure pharmaceut compani wa headi year
european pharmaceut group prove ultim counter cyclic stock sector report sale grow th averag per cent past month
although pharmaceut market remain buoyant horizon without cloud
research develop cost rise inexor time govern begin balk ever increas cost drug
western govern grappl ever increas health care budget
germani exampl health cost per cent gnp
drug form signific proport cost design easi target recess batter govern
germani pharmaceut spend repres nearli per cent health care cost itali portug repres per cent
price like come increas pressur come year
sparkl perform pharmaceut group last month ha help posit
us world largest drug market senat edward kennedi ha conduct vocal campaign restrain price increas drug sold public health servic fund institut
wave price legisl present sweep congress question sector price structur
debat also open last year whether uncontrol health care cost becom full blown contagion one wa sap nation competit standard live
far clear whether pharmaceut industri tradit defenc need reinvest profit research develop requir return signific risk involv drug develop stand current polit tide
outsid us govern al readi attempt limit drug expenditur
list product doctor forbidden prescrib patient receiv onli partial reimburs
profit control insist limit return capit employ
encourag gener non patent cheaper product
time pharmaceut group continu struggl inexor rise research develop cost
grow th cost partli explain increas complex new drug
ha also caus grow th regul test safeti qualiti efficaci drug
mean recessionari storm appear set durat basic chemic industri
dark cloud may also gather pharmaceut sector
market wa quick interpret yesterday half year figur glax evid zantac falter
underli grow th ulcer drug wa certainli recent month period buyer strike itali obligatori medicaid refund us exagger trend
even disappoint glax overal sale constant exchang rate increas impress per cent six month per cent financi year whole
prospect new gener glax drug littl clearer
anti emet product zofran look like hit pound sale full year question remain whether sold treat ill
juri remain migran look set receiv us approv thi summer scare affect serev
investor take encourag news market expens fall proport sale increas r spend futur mirror sale grow th
perhap one third equiti us hand key next share price move almost certainli lie wall street
comparison may pertin year world economi wa come recess zantac approv us
first half saw continu outperform though back sort heavi us demand nine year later may run steam
second half saw sharp underperform wipe rel gain first six month
ft feb denmark ask ec look glax price
glaxo uk pharmaceut group challeng european drug price strategi
danish offic fair trade ha ask european commiss investig whether compani abus domin market posit charg excess high price drug
glax strategi command premium price innov product could sever undermin danish move success ful
group need gener substanti revenu new pharmaceut product next year compens expect fall sale zantac best sell ulcer drug
danish author complain price three recent introduc product
three drug describ analyst possibl blockbust potenti sale dollar bn pound year
analyst fore cast migran gener revenu dollar bn year
order prove glax abus domin posit commiss show charg excess price conduct analysi cost produc drug
european court justic ha rule past price excess reason relat econom valu product
glax said last night wa studi danish complaint
compani said drug price reflect benefit product societi patient well cost research develop
expect spend pound r thi year
mr robin gilbert analyst jame capel said danish move wa unpreced
said complaint wa unlik much effect sale short term could signific long term made govern question glax price polici
thi unplea ant straw wind ad
danish announc befor london stock market close led p fall glax price
well come increas presenc intern pharmaceut market
compani found make compress medicin tablet ha becom one world fastest grow pharmaceut busi
propos sale medic chariti well come trust much control stake compani fulli enter commerci world
sati fy rigor demand institut sharehold greater manag freedom run busi
sinc per cent well come share float stock market ha becom one largest public compani uk
trust sir henri bequeath compani ha seen valu sharehold grow point feel must reduc
time flotat sir alfr shepperd chairman chief execut retir insist group wa commerci busi run make profit
sinc compani ha becom much stronger competitor world drug industri
research scientist could enjoy work well come though academ institut
compani would pursu scientif fascin rather commerci promis
mr john robb chief execut well come ha pursu restructur programm aim sharpen busi increas profit margin
strategi near complet support trust plan sell larg part stake
previous fear larg sale would di ruptiv
part thi programm sever tough decis taken
group gave work tpa blood clot dissolv drug
wa hard mr robb say pound spent
well come realis would difficult make commerci success product
measur includ sale peripher activ margin low
includ busi vaccin well come strong sentiment attach
cut head includ per cent job london head offic
well come ha also made much determin effort market drug
result compani fast profit grow th slow financi year ha resum
thi year pre tax profit fore cast top pound rise pound
balanc sheet strong net cash pound end august last year
stori well come stock market career ha domin retrovir high profil aid drug
launch still onli wide use treatment condit
compani share price ha fallen often risen eb b flow news retrovir
ha arguabl best record ani uk drug compani turn research develop new product
ha acceler rate launch new drug develop product almost everi year past decad
well come strength research domin anti viral market basi grow th
best sell drug zovirax use treat herp shingl chicken pox wa launch
onli patent approach end live realis full sale potenti pound year
sinc mr robb join compani march deputi chief execut co market deal higher price zovirax improv profit margin
retrovir zovirax face problem launch new market although public surround aid ha meant greater public awar retrovir
sale grow th sinc launch ha outstrip zovirax initi year
retrovir wa well market might say mr jonathan de pass industri analyst barclay de zoet wedd
possibl well come fail maximis drug sale therefor profit also reflect compani per cent gross profit margin lower competitor drug busi ici glax fison
well come new found market prioriti import non prescript drug busi
note cough cold remedi actif sudaf counter otc product bought without prescript calpol pain reliev infant
aggress market also prepar ground sale zovirax treatment cold sore without prescript
mr robb deni busi sell low technolog otc cure place research driven compani
signific posit otc becom increasingli import pressur price prescript drug increas
margin squeez prescript drug well come turn otc drug stabl sourc incom
glax exampl dispos otc drug sever year ago mr robb see otc mean extend profit earn life drug
prescript drug lose patent rival produc drug cheapli
hope turn prescript drug brand consum product premium price maintain
al readi zovirax sold counter new zealand
smith kline beecham ha similar philosophi
ha earmark ulcer treatment tagamet onc world best sell drug otc sale treat upset stomach
well come seek partner expand intern otc busi
well come need market partner confin otc drug
strong sell anti viral drug new product essenti group profit grow th area ha littl experi
includ epilepsi muscl relax oper hepat b eventu potenti big market migrain treatment
new drug need compens eventu declin zovirax
investor consid whether buy share releas trust decid whether promis product pipelin enabl well come continu strong stock market perform
freer hand key product drug treatment estim sale sale pound pound zovirax anti viru retrpvor anti aid exosurf lung treatment prematur babi wellferon hepat b lamict epilepsi new launch bw u replac bw c zovirax launch sourc
well come bz w lehman brother top uk trust grant asset pound pound well come trust
ft apr glax head french oper leav compani
glaxo presid french oper mr edwin nathan ha left compani follow break relat british group french govern price migran new migrain drug
glax refus give reason hi move
wa charg negoti french govern migran
last month told french new spaper exchang high price migran glax would construct f fr bn pound factori franc set research develop centr co market drug sanofi french pharmaceut group
deal common franc though normal refer public
told le echo french financi daili
differ minist drag negoti perhap order take risk befor next elect
point franc wa one last european countri licens migran
two week later french govern order investig ethic legal medic accept method use glax market migran
set commiss decid whether k european commiss investig possibl abus market posit
french offici said concern glax wa gener public pressur govern licens drug
particular irrit number articl migran consum magazin
franc tradit ha low pharmaceut price ha among largest per capita consumpt drug europ
per cent gnp last year health care second highest spend europ germani
glax ha strategi charg high price innov product
group like pharmaceut compani find hard maintain price exist product japan europ
us mani forc polit pressur introduc voluntari price freez promis increas price abov rate inflat
mr nathan replac mr christoph adam glax commerci director
glaxo pharmaceut group uk biggest compani market capitalis ha fifth award technolog antibiot zinnat
zinnat wa develop becaus drug class need inject therefor littl use outsid hospit environ
addit bacteria build resist exist antibiot penicillin prove increasingli less effect
challeng glax wa develop drug wa
activ ingredi within zinnat cefuroxim axetil extrem unplea ant tast
stabl water retain potenc within stomach gut
resist enzym gut could ingest effect bodi
quick act onc taken blood stream
without ani toxic product therefor without seriou side effect
abl resist beta lactamas substanc excret bacteria prevent antibiot work effect
glax believ test mani differ formul greenford research centr north west london period six year befor discov right drug
pharmacist also invent new process manufactur wax coat around drug
coat wa unplea ant tast dissolv requir gut releas activ ingredi
sinc wa launch peopl treat drug
zinnat use larg number infect rang upper respiratori infect tonsil sinus urinari tract infect gonorrhoea
clinic trial show cure improv achiev per cent patient lower respiratori infect per cent patient gonorrhoea
zinnat also ha low incid side effect
pound sale gener drug sinc launch accord glax make second best sell antibiot class
previou award technolog ventolin becotid asthm drug zantac ulcer treatment world best sell medicin fortum anoth antibiot
glax ha spent nearli dollar bn research develop last year
last fiscal year alon glax spent dollar research develop expect analyst spend dollar bn ani compani
ft jun market prescript well come john robb talk prospect drug group
wellcom chief execut mr john robb pride hi market orient approach busi
year old scot former consum product execut beecham ha prove determin make group market driven sinc wa appoint chairman sir alistair frame juli
mr robb face biggest market challeng hi life sale per cent group largest ever issu privat british compani
offer schedul mid juli could rais much pound bn
compani fastest grow among world largest pharmaceut compani
five year averag well come ha enjoy highest earn per share grow th rate ani pharmaceut stock
addit compani ha domin posit per cent fast grow anti viral market
sale zovirax herp treatment expect grow per cent dure next two year reach pound
retrovir anti aid drug also known zt could reach annual sale pound accord recent note sg warburg compani broker
although well come short term futur look bright mr robb task complic two doubt long term grow th
first benefici effect group wide rang dispos programm run next year
sinc took helm oper margin improv
dure first half thi year rose
howev half improv came programm dispos come end
dure first half sale increas per cent
comment believ much per cent well come revenu grow th could come thi product next year
main patent expir germani next year uk us japan
sale still grow remark fast given wa launch mr robb say recognis threat zovirax ha develop twin strategi deal problem
first element consist two new compound known u c eventu replac zovirax
two drug launch although still clinic trial
smith kline beecham mr robb acknowledg ha excel market track record schedul launch competitor drug famciclovir
element mr robb defenc strategi sell zovirax without doctor prescript chemist
market clout exploit zovirax otc counter market admit mr robb
play anoth possibl threat retrovir well come anti aid drug
argu analyst one stage becam fixat retrovir see group mere relat aid although drug repres onli per cent group turnov last year
competit retrovir new drug unlik make much impact medium term reckon mr robb
view aid continu treat retrovir combin therapi least next five year
market grow competit nois anyth els moment
concern doe exist challeng retrovir us patent howev
patent valid challeng barr laboratori us group
come case unclear sinc decid next year juri north carolina
well come lose plan appeal barr would probabl abl market gener version drug mean
spite problem face group mr robb confid deliv target ha promis
includ underli sale grow th excess per cent oper margin per cent earn per share grow th per cent year
group research develop ha becom much focus say
compani remain commit stand research ha adopt project manag approach perfect glax involv drop compound fail reach develop target time
sinc septemb number compound develop ha fallen
drug fulli develop launch possibl market justifi money invest cost dollar pound bring drug market
great reput research develop compar reput market say
use think got research develop right product would sell themselv
plan improv market expand well come sale forc
ha also hire new sale manag us japan
els continu hi strategi co market compani
incred import rais market skill level research develop skill say mr robb
launch world wide market campaign thursday hi immedi challeng make sure flotat doe run troubl
much pound bn stake hi much vaunt market skill demand
cornerston econom develop pharmaceut thrive montreal
western suburb montreal illustr turnround quebec pharmaceut industri declin earli cornerston econom develop
hoffman la roch canadian arm swiss multin built extens new research manufactur space pastor vaudreuil
multi storey tower five storey build alongsid design st centuri
feder govern introduc compulsori licens import product reduc basic patent protect brand name medicin four year
compani never move space age facil
american base concern built new research lab area
hoffman la roch move canadian head offic ontario canadian research facil us
wait sever year sell vaudreuil ventur
brand name compani maintain patent protect reduc clear advantag gener produc name lower drug price
warn compulsori licens system would work canada quebec
earli ayerst mckenna harrison close montreal laboratori merg parent us research oper
canadian financi back one group found new compani specialis product treat diseas immun system cancer viral diseas
six year old b chem pharma ha yet show oper profit boast market valuat cdollar bn
glax canadian partner develop anti aid drug
big chang came ottaw bow pressur multin agre extend patent protect seven year return promis sizeabl invest canada
western suburb montreal display result invest spree follow
nearli dollar ha invest brand name intern domest compani new research laboratori product plant quebec sinc
montreal ha becom undisput centr canada pharmaceut industri
merck frosst canada burrough well come bristol myer squibb pharmaceut group b chem pharma among led way
feder govern plan extend patent protect line intern practic end compulsori licens
want govern adopt legisl place canada level play field jor industri nation protect pharmaceut product say mr michael carnow presid merck frosst canada
thi enabl canada quebec compet invest
said gatt deadlin agreement patent protect slip canada move unilater ensur canadian base compani compet
merck frosst ha begun engin work big manufactur expans montreal
new plant gear specif product intern market
compani canadian research budget cdollar includ new dollar research centr open last septemb
colin mallet presid sandoz canada say invest spree continu
predict hundr new research product job creat quebec canada thi decad condit favour
quebec govern like work hard ensur bulk new invest come provinc
pharmaceut repres one quebec three import competit industri cluster employ research plan invest dollar
almost half total canadian pharmaceut industri half annual dollar research effort locat quebec
provinc ha four univers faculti medicin two pharmacolog faculti array specialis bodi montreal clinic research biotechnolog research heart cancer institut
research also carri laval univers quebec citi
quebec industri activ rang basic appli clinic research biotech engin
product includ fine chemic pharmaceut therapeut product vaccin biolog diagnost product
quebec industri invest dollar research per cent total wa higher
also includ gener produc though congreg mainli ontario
feder govern consid extend patent protect period year applic equival year market place
popul age industri play crucial role economi say mr mallet
move toward longer protect partli becaus test last longer complex
must provid environ foster competit industri countri scientif expertis patent protect
dice still load canada becaus local market lost gener manufactur onli seven year
canadian firm research must given fight chanc
gener produc react strongli suggest patent protect extend significantli
mr barri sherman presid apotex toronto one canada two biggest gener drug maker said govern ha capitul us pressur
apotex go ahead plan dollar extens winnipeg plant
mr gerald tremblay quebec industri minist stand behind hi desk energet spread af brightli colour chart front like croupier deal baccarat card road map explain quebec latest initi draw govern busi labour academia togeth concert industri strategi
mr tremblay ha mba harvard univers ask rhetor
diagram complex pattern lilac orang pink box box multi colour repres one industri cluster
sector quebec believ best chanc competit world market
aim encourag manufactur industri co oper close supplier govern trade union univers research creat effici technolog advanc industri
corporat ha cornerston quebec econom polici past year
contract hydro quebec big jame bay power project put muscl quebec engin construct industri
govern direct financi support help attract pharmaceut aerospac compani provinc
get everyon pull direct ha rel easi provinc tightli knit homogen popul
far job hop senior rank busi govern quebec part canada
howev implement far reach industri strategi less simpl use
abil govern use financi support tool industri polici constrain cdollar bn budget deficit
furthermor hydro quebec construct programm slow sharpli second half decad forc mani local compani look el se contract
mr pierr fournier research director leve que beaubien geoffrion quebec lead secur firm predict govern abl give littl moral support new industri cluster concept
like go take long time mr fournier say
five sector aerospac pharmaceut inform technolog product power gener equip metal process well establish domest intern market
accord mr paul lussier director invest servic ministri industri commerc quebec ha reach point jor pharmaceut compani doe anyth north america without consid quebec option
could five six sector great shape
second group includ transport equip petrochem agri busi textil cloth forestri hous environment product cultur industri
sever sector face sever competit pressur recent year need shake fulfil hope place
inclus cluster partli recognit provinc natur resourc sector vital import region develop
group industri ha set task forc identifi strength weak
addit provinc region ask submit cluster wish list within next month
mr tremblay see govern role catalyst
big puzzl put piec togeth say
exampl vigor arm twist quebec ha persuad feder govern locat new canadian space agenc montreal
forestri technolog centr ha move ottaw quebec citi
among product collabor busi take shape institut pharmaceut research montreal
twenti one brand name gener drug maker contribut cdollar
feder provinci govern chip anoth cdollar
spite budget constraint govern money avail individu compani
sinc govern ha provid busi cdollar loan
princip repay modernis loan exampl normal start onli seventh year
research develop expens enjoy tax credit per cent
effort nudg academ toward practic research credit doubl r undertaken partnership univers
foreign invest import part quebec industri strategi
us european asian compani larg stake mani cluster well part economi
two south korea biggest north american invest quebec form hyundai car plant eastern township sami steel factori montreal
much emphasi year ahead attract asian capit
govern ha open trade invest offic vancouv mandat tri divert quebec money flow canada western provinc hong kong taiwan singapor
british biotechnolog group yesterday publish path finder prospectu intern share offer plan juli
oxford base pharmaceut compani say aim rais pound sell per cent equiti share issu london new york
issu expect price p p valu compani pound
british biotechnolog use proce flotat primarili fund research develop programm cover four medic area
ha two drug undergo earli clinic trial third due begin clinic test august
group doe expect market gener revenu commercialis pharmaceut product least latter half
japanes drug maker slow mark pharmaceut group pressur expand innov
rush invest oversea japanes pharmaceut compani late appear signal entranc world stage
howev ha sinc becom clear japanes pharmaceut group far becom toyota matsushita global drug market
despit strong effort japanes group countri pharmaceut industri ha unabl develop world beat innovatori product need break oversea market
yamanouchi pharmaceut annual sale bn dollar
bn one drug compani expand aggress intern hope truli global compani within next year
fujisawa pharmaceut japan third largest sale bn say
essenti japanes compani globalis sinc domest market condit go increasingli difficult
mr thoma hofstatt execut manag director hoechst japan say japanes drug compani go take time grow lead global oper unless real breakthrough product discov
japanes drug compani start oversea expans simpl licens agreement establish clinic trial offic
ambiti howev set joint ventur acquir distributor us europ
fujisawa acquir lyphom small drug compani us yamanouchi built manufactur plant ireland research centr oxford last year acquir pharmaceut divis gist brocad dutch chemic compani
japanes drug maker tri build comprehens independ oper research develop product market
fujisawa increas product market capac us europ ahead launch fk immun system suppressor use prevent transplant patient reject new organ
howev compar multi billion dollar merger acquisit us european compani japanes oper acquisit modest size
total oversea sale japanes pharmaceut compani remain around per cent turnov compar per cent lead us compani per cent lead european compani
main barrier japanes compani ha lack market product lag develop import new drug
thi wa due relianc small step innov exist drug mainli lower valu antibiot vitamin
mr muneyuki sakai pharmaceut analyst counti natwest tokyo say oversea subsidiari need least four five origin mainlin product
except thi pattern includ sank yo anti cholesterol product mevalotin
yamanouchi known anti ulcer agent gastar bn oversea sale last year
japanes drug compani tradit complac r becaus govern price polici drug
health ministri use award new drug premium price whether improv fail give drug compani incent develop innov drug
rather take risk spend high sum product develop mani larger compani chose onli make small improv exist drug distribut drug suppli foreign compani licenc japanes market onli
develop programm also hurt cumul price cut health ministri start
forc per cent price reduct everi two year
thi pressur cash flow japanes drug compani consider smaller western counterpart
howev attitud toward r chang rapidli innov ha becom key profit
ministri push innov drug chang price rule
thi fiscal year onli drug allow premium price repres new concept effect exist drug make notic contribut treatment
time foreign drug compani start end distribut tie establish network japan reduc commiss former japanes partner
ultim compani need establish worldwid presenc order recoup mount r cost
fujisawa need globalis becaus market share japan ha hit ceil profit reach upward limit
compani succeed intern see pressur profit
long run japanes compani expect becom innov
howev compani whose develop polici aim margin improv chang direct easi
mr john wilson analyst jame capel say
compani pressur sale industri grow per cent cost r increas per cent
sinc typic drug take year bn develop onli compani larg enough absorb cost abl surviv
mr sakai counti natwest believ compani led sank yo fujisawa yamanouchi abl establish posit intern pharmaceut market
near futur compani predict wave merger acquisit especi rescu smaller compani lack new product
merger acquisit foreign compani line merck banyu recent bohring ingel im yamaguchi seiyaku also expect increas japanes compani cheaper follow slump japanes share price
well come sale could rais pound bn
wellcom trust medic chariti indic yesterday would sell share well come drug compani next month intern tender offer
yesterday close share price p p offer would worth pound bn
prospectu publish yesterday said group expect pre tax profit earn per share year august significantli higher financi year
analyst fore cast profit pound pound earn p per share
mr lawrenc bank head corpor financ robert fleme merchant bank co ordin global offer said figur wa conserv wa veri confid would excess demand
mr roger gibb chairman trust said strong interest shown
provision alloc give uk market us japan remaind spread around rest world
within uk portion pound worth share earmark public offer
compani today start present investor citi
offici tender process start juli expect close juli
tender price basi alloc announc juli deal suspend first hour trade day
mr john robb chief execut well come said yesterday would emphasis five drug group strength potenti buyer
includ group domin grow anti viral drug market promis research develop pipelin emphasi sale market
also point well come strong volum grow th sale limit effect price pressur drug abil increas margin
mr bank said retail demand wa hard estim
far peopl rung well come share inform offic
well come ha individu sharehold regist employe
region stockbrok prepar appli behalf privat investor also particip via applic form
exist well come sharehold address uk receiv special applic form give prioriti pound worth share
retail investor offer buy share tender price fix intern book build process
howev tender price announc day public offer close applic must specifi valu share wish buy minimum pound
sale share would reduc trust stake
trust increas issu fleme ha option sell per cent final size
maximum sold trust would left per cent say would retain long term invest
trust pay total commiss per cent valu share sold
paul abraham examin issu share uk pharmaceut group
mr john robb chief execut well come pharmaceut compani pack hi bag today head hi nativ scotland
edinburgh hi first stop round world road show take citi san francisco osaka
hi travel aim promot sale least share worth pound bn
mr lawrenc bank head corpor financ robert fleme advis well come trust chariti current hold
per cent well come wa optimist offer yesterday
pleas level interest uk intern thi first rate pharmaceut compani said
spite mr bank rhetor issu success hang balanc
follow last week abort flotat gpa aircraft leas group look new issu ha cloud
world drug market grew averag per cent year
industri fore cast put figur per cent
five year could see littl per cent averag grow th
last autumn prepar well come offer began mr robb sale task appear easier
pharmaceut share star perform global market
januari decemb british health care stock driven american buy outperform uk market per cent
period american drug stock outstrip us market per cent
age popul develop countri ensur demand drug continu grow even dure recess
guarante earn grow th far excess experienc sector
sinc januari us pharmaceut share underperform market nearli per cent
american investor note appar upturn us economi switch recess proof stock perform better dure recoveri
well come ha seen similar shift uk
befor issu wa announc march p yesterday
investor enthusiasm ha also dampen increasingli hostil environ drug compani
cost associ research develop market drug rise fast becaus drug must go expens licens procedur individu countri time
mean revenu threaten worldwid downward pressur drug price govern struggl contain ever grow health expenditur
us group disappoint first quarter result thi year
share bristol myer squibb world third largest drug compani fell per cent june warn sale grow th second quarter would less per cent
thi difficult background mr robb must set hi case
first must convinc doubt audienc ha adopt right strategi well come escap twin pressur rise cost fall price
must answer misgiv ani perceiv compani weak
crucial part hi tour start next friday mr robb start hi us campaign
morgan stanley us invest bank advis well come charg success ful sell larg volum
although issu onli half us largest public stock offer last month gener motor rais dollar
bn british compani wide known north america
onli per cent stock us compar per cent glax uk pharmaceut group per cent smith kline beecham anglo american compani
anoth problem mr robb us campaign well come price earn ratio slightli higher merck world largest drug compani last year one us investor favourit stock
mr steve plag pharmaceut analyst counti natwest onli import uk broker directli involv issu explain
calcul well come prospect price earn ratio wherea merck glax
question whether us investor buy stock higher ratio merck
nevertheless mr robb point sever factor hi compani favour
well come fastest grow world largest pharmaceut compani
past five year ha enjoy highest averag annual earn per share grow th rate ani big pharmaceut compani
short term spite difficult condit well come earn grow th look assur
g warburg compani broker fore cast recent circular sale continu oper set grow per cent year next three year
mean oper profit margin period increas
strongest card mr robb hand compani abil stand price pressur
dure past six month sale increas per cent period
onli percentag point came price increas
rest wa gener volum grow th
littl disagr robb hi new manag team done excel job earn grow th look strong next two year said mr plag
signific risk earn grow th may start deceler
mr plag claim two main motor earn grow th compani sale less profit subsidiari zovirax anti viral treatment start run steam soon
unusu year old product zovirax sale still grow fast
grow th like slow mid despit well come acquisit licenc around world zovirax treat diseas chicken pox shingl
drug patent expir germani follow uk us per cent sale made
patent expiri could signific becaus much well come grow th deriv zovirax
mr plag estim product could account per cent sale grow th next year
long term prosper well come depend upon develop new product replac exist earner
compani strong research base clearli crucial mr robb say r invest remain per cent sale forese futur
sinc join compani beecham wa consum product execut mr robb ha tri integr r close market effort
symbol group market oper move beckenham r site provid far closer co oper two divis
use think got research develop right product would sell themselv
rather build expens market network howev group turn co market agreement compani
ha initial deal hoechst germani sigma tau itali sumitomo japan help market zovirax
last spring compani conduct thorough review r project undertaken
aim wa avoid research scientif interest commerci fruitless compound
result numer product drop leav resourc fewer potenti lucr drug tovaquon well come medicin aid relat pneumonia
mr robb ha also move set clinic trial simultan japan europ us well come new herp treatment known
previous trial carri consecut lead long gap approv market
project team establish anticip potenti delay regulatori author
mr robb hope could roll world three largest market us japan europ within month
spite mr robb effort weak remain
well come corpor tax rate exampl rel high becaus ha move part manufactur base countri singapor puerto rico liber tax regim
per cent profit tax contrast glax per cent merck per cent
g warburg said circular expect well come tax burden increas percentag point thi year
anoth concern retrovir well come anti hiv drug
patent challeng barr laboratori us gener group seek market version drug
well come case technic strong case decid north carolina juri next year said mr plag counti natwest
retrovir aid emot issu come mean certain
well come lose group earn grow th could fall significantli
although drug ha high name recognit repres onli per cent group sale
robert fleme mr bank wait juli offer close see whether hi optim justifi
mr robb jet round world hi market skill like much demand
despit question surround well come long term grow th like ensur issu succe
new era look mind drug second articl seri drug research clive cookson line treatment mental condit anxieti memori loss
pharmaceut industri ha abysm record treat disord brain nervou system
new drug transform look peopl suffer infecti ill heart diseas gastro intestin problem psychiatr patient depend medicin discov sever decad ago
current treatment mental condit mild anxieti sever psychosi emerg dure black box era drug discoveri
doctor observ reliev symptom often poorli unpredict pharmacologist idea work
seriou problem degen brain diseas alzheim still noth realli work
look howev much brighter scientif discoveri chemistri biolog brain find way new drug
one introduc dure base understand neurotransmitt chemic messeng send signal cell receptor protein molecul cell receiv signal initi specif biolog respons
year prospect far superior treatment base genet process involv mental disord
best known neurotransmitt ht also call hyroxytryptamin serotonin activ onli brain also part bodi
associ sever type receptor give differ biolog respons
pharmaceut industri develop drug interact specif type agonist stimul receptor antagonist block
glax uk ha investig ht system almost year expect spectacular payback two drug
sumatriptan trade name migran first effect treatment migrain intens recurr headach suffer least one adult
wa launch last year inject introduc uk thi month conveni form pill
sumatriptan ahead competit potenti sale huge pound bn year overcom doctor fear side effect
sumatriptan agonist ht categori receptor stimul uptak ht cranial blood vessel
glax hope sumatriptan would effect el se bodi experi show patient feel tight chest inject
presum becaus blood vessel el se bodi contain ht receptor
glax say sumatriptan side effect insignific healthi peopl show difficult make select receptor base drug
ondansetron zofran antagonist differ receptor type ht
wa launch two year ago anti emet prevent nausea vomit induc cancer therapi glax carri clinic trial ondansetron rang psychiatr condit includ anxieti schizophrenia addict age associ memori impair
glax research understand cautiou proclaim ondansetron psychiatr wonder drug
blanch outsid talk potenti smart drug could improv everyon memori
mike tyer pharmacolog director glax group research say ht receptor neuron nerv cell brain seem control thing go wrong
everi thing work properli fairli silent
ht antagonist ondansetron may help restor balanc sever disord without side effect
anoth group new drug base ht system lead improv treatment depress
specif serotonin uptak inhibitor ssri known increas low ht level brain associ mani form depress
eli lilley us al readi sell dollar bn year pioneer ssri fluoxetin prozac launch
hot pursuit second gener ssri led paroxetin seroxat wa develop jointli novo nordisk denmark smith kline beecham anglo american group
ssri fewer side effect tricycl drug domin antidepress treatment year
yet ssri still leav much desir
take least two week reliev depress fail work one third patient
may reflect partli poor qualiti clinic diagnosi depress non acut mental disord
scientist believ form depress ultim work common biochem pathway
right everyon agre theori may eventu possibl find fast act drug help anyon clinic depress
greatest neurolog challeng pharmaceut research find cure degen brain diseas lead inexor dementia death
preval alzheim affect mani per cent peopl
search alzheim treatment ha led new class drug nootrop develop enhanc memori cognit function
first gener nootrop aim increas amount acetylcholin brain
alzheim patient mark deficit thi neurotransmitt
alzheim drug develop recent work indirectli inhibit enzym call cholinesteras break acetylcholin
although shown promis clinic trial manufactur yet produc evid strong enough convinc us food administr licenc ani drug
du pont merck pharmaceut joint ventur du pont merck us ha promis anti dementia drug late clinic trial work differ way
act directli stimul releas acetylcholin neurotransmitt brain
drug chemic name linopirdin noteworthi unusu vivid appeal trade name aviva
howev none memori enhanc drug even aviva temporarili revers slow mental degener characterist alzheim diseas
none prevent build tangl plaqu amyloid protein progress destroy patient brain
best long term hope cure progress dementia identifi genet mechan respons develop drug block effect
case alzheim fault gene code amyloid precursor protein app seem respons
famili thi inherit often caus environment factor
mani pharmaceut research work long rang project block app though hamper fact yet good anim model alzheim
athena neurosci california one biotechnolog compani furthest advanc thi area
futurist still idea repair brain damag grow new nerv cell
doe normal occur adult brain scientist accumul evid select regener could achiev remov genet factor inhibit process
seri continu next month look asthm drug
ft jun cancer chariti pioneer drug deal
cancer research campaign uk chariti ha sign deal us pharmaceut compani develop pioneer cancer treatment could earn chariti much pound year
drug call temozolomid first effect treatment glioma form brain tumour
cancer research fund research develop drug wa origin discov aston univers birmingham
clinic trial establish drug effect form cancer set
professor edward newland head cancer medicin chare cross westminst medic school director drug clinic trial said may prove effect bone marrow cancer
agreement schere plough largest ever conclud chariti wholli technolog transfer compani worth immedi dollar
onc drug launch chariti receiv royalti payment
could worth pound year accord dr sue foden manag director cancer research campaign technolog chariti technolog transfer subsidiari
last year chariti incom rais mainli voluntari contribut wa pound
agreement chariti receiv per cent royalti worth per cent per cent sale depend volum
remain per cent royalti paid rhone poulenc rorer franco american compani help initi research aston univers discov molecul chare cross westminst medic school develop
professor newland explain half glioma patient use drug shown clinic benefit mani per cent demonstr improv examin brain scan
patient skin cancer also shown improv
said thi wa first time drug repeat noteworthi effect brain tumour
chariti said hope schere plough would abl use us food drug administr acceler licens programm medicin would american market within five year
potenti market temozolomid wa difficult predict becaus depend whether work cancer professor newland said
healthi market pharmaceut grow access japan drug sector
year sit back seat world lead pharmaceut compani oper japan start gain presenc use one introvert sector countri
recent japanes drug compani market virtual themselv import account less per cent total sale
howev recent fall asset valu along industri restructur creat chanc intern drug compani expand japanes oper
countri drug market second largest world us annual sale bn dollar bn hold substanti potenti grow th popul age rapidli japanes consum becom increasingli health consciou
mr thoma hofstaett execut manag director hoechst japan say
pharmaceut compani truli global must maintain presenc us europ japan
howev recent foreign compani lack distribut network forc reli tie japanes compani
although acquisit lead foreign compani date back far merck us purchas per cent banyu pharmaceut medium size list compani case rare
recent fall stock real estat market trigger activ among foreign drug compani
earlier thi year pfizer us drug chemic group announc plan buy koshin medic privat medic equip distributor estim bn
last year monsanto us acquir per cent hokuriku pharmaceut
bn roussel medica merg morishita pharmaceut
lead european drug group also shown interest purchas japanes compani
banker point smaller japanes drug maker wholesal welcom foreign drug compani compar advantag japanes counterpart
price cut ministri health welfar implement everi two year averag per cent squeez profit drug manufactur
small medium size compani lack new innov drug face increas difficulti
japanes drug wholesal also forc chang busi strategi becaus price cut
past manufactur wholesal special keiretsu corpor group type relationship
howev price cut continu depress profit margin wholesal need distribut wide rang product rather one manufactur
last april japan fair trade commiss ban manufactur distributor manipul drug price ha also broken cozi relationship
mr kenji wakamatsu sandoz pharmaceut say
sinc wholesal freedom much easier foreign compani establish tie
foreign compani enter japanes market earli start set sale market oper
sandoz enter market distribut tie sank yo second largest japanes drug maker set distribut network
bayer also end sale tie takeda industri leader
mr hofstaett hoechst say key success number strong product
bayer adalaat calcium antagonist post sale bn last year becom second best sell drug japan
nippon roch furtulon anti cancer agent also see brisk sale
mr john wilson pharmaceut analyst jame capel tokyo say
japan profit market foreign compani sinc al readi effect drug need spend fortun research develop
mani foreign compani final stage set full oper product sale research develop
bayer invest bn new research centr sandoz expand product plant north tokyo expect new research laboratori complet next year
contrast foreign car electron maker foreign drug compani hold per cent market say treat equal japanes
one problem remain clinic test new drug foreign compani must present data clinic trial japan
howev ministri health welfar loosen grip japanes compani ventur abroad drug oversea data pre clinic test accept
top ten foreign drug compani japan sale chang ybn year banyu merck
figur dec except banyu mar glax june
fresh water gene pool explor role genet drug play cure diseas sourc
entir new gener drug act directli human gene like transform pharmaceut industri next two decad
genet drug sale could worth ten billion dollar year within year
almost everi drug today act protein chemic work live creatur virus peopl
rapid expans genet knowledg ha made possibl target drug origin caus troubl gene tell cell exactli protein make
al readi scientist know sequenc function thou gene human anim plant micro organ expect within year discov estim gene provid blueprint everi human
genet drug aim either defect gene patient cell infecti organ virus
promis cure diseas hard treat exist medicin
exquisit specif use favourit phrase biotechnologist avoid side effect today protein base drug
two broad categori genet drug begin clinic trial
gene therapi involv insert new gene cell produc therapeut protein bodi
anti sens therapi code block opposit process switch gene stop make harm protein
common view biotechnolog industri last year wa anti sens commerci potenti gene therapi least medium term becaus principl simpler process
specif gene switch molecul small enough made orthodox chemic synthesi
gene therapi hand requir whole new gene thou time larger anti sens drug ha made biotechnolog
also appear immens problem deliv new gene cell need get work
last month anti sens research ha continu make progress
isi pharmaceut california ha start clinic trial anti sens drug treat human papilloma viru caus genit wart cervic cancer sever us compani specialis anti sens technolog includ genta gilead hybridon targetech develop drug aim wide varieti diseas
viral infect hepat b aid herp
gene therapi move forward even faster scientif commerci front view emerg pharmaceut industri eventu import anti sens technolog
research us nation institut health nih carri first human gene therapi trial septemb four year old girl kept apart children becaus one defect gene immun system meant natur protect infect
everi month sinc ha receiv transfus billion blood cell copi correct gene ad treatment ha repeat becaus genet engin cell gradual die
immun defenc strong enough attend school normal
success led flood propos gene therapi experi us clinic develop genet medicin well ahead europ japan
american regul al readi approv clinic trial anti sens start compani ru hing exploit technolog
therapi inc gti base maryland near nih enjoy close relationship pioneer gene therapi research
includ somatix therapi viagen target genet tran karyot therapi vical
rang treatment propos gene therapi even wider anti sens
candid treatment near futur includ inherit singl gene disord cystic fibrosi haemophilia
eventu may possibl treat combin genet fault heart diseas degen brain diseas valuabl target
give patient cell abil produc therapeut protein normal present bodi
thi ha potenti treat mani form cancer
even rapid progress last year howev research still overcom sever technic problem gene therapi anti sens becom mass market treatment
import develop better way enabl genet therapeut reach cell need
first gener anti sens drug design reach difficult site insid bodi
genta appli bone marrow cell remov temporarili bodi switch cancer caus gene leukaemia isi target viral gene herp papilloma infect near skin
earli gene therapi trial use genet engin virus insert new gene patient cell
although viru disabl prevent caus ani harm research cannot rule slight risk might stimul latent infect even trigger cancer
new deliveri system prospect categori genet treatment
anti sens drug link chemic make permeat cell effect non viral vector develop gene therapi
recent establish pharmaceut giant left gene base medicin academ scientist biotechnolog start
scrambl catch start research hous form allianc specialist biotech compani
isi exampl ha partnership ciba geigi switzerland eisai japan rhone poulenc franc
gilead competitor ha collabor research agreement glax uk
gti work sandoz switzerland ha shown interest gene therapi ani larg pharmaceut compani
research talk total sale genet drug run ten billion dollar within year though estim highli specul
robertson stephen co californian invest analyst say us gene therapi market three cancer renal ovarian melanoma potenti worth dollar
bn year base cost dollar per patient
seem expens may accept price treatment save onli patient life also ten thou dollar hospit fee
compani focu new drug research japan drug industri
mount worri intern expans japan pharmaceut industri follow counterpart vehicl electron industri calm slower expect result oversea oper drug group
howev japanes pharmaceut industri turn point compani shift focu toward product new effect drug boost research develop
compar western counterpart japanes drug compani oper smaller scale focus domest market second largest world annual sale bn
compani tradit reli small step innov exist drug mainli lower valu antibiot vitamin
howev declin profit domest oper brought recent reform ministri health welfar ha forc compani shift emphasi r order creat world beat innovatori product
recent japanes drug compani complac r becaus govern drug price polici new drug award premium price whether dramat improv
compani lack incent develop innov drug chose onli make small chang exist drug rather spend big sum product develop
compani also reli profit margin distribut drug suppli foreign compani licenc japanes market
push govern new effect drug ha prompt chang price rule
thi fiscal year onli drug allow premium price repres new concept effect exist drug make notic contribut treatment
profit compani lack new product squeez govern offici price cut implement everi two year averag per cent
cut appli pressur compani produc new drug becaus impact profit margin new drug less sever
addit foreign drug compani start termin distribut tie establish network japan reduc commiss former japanes partner
compani increas r capit invest spend need establish worldwid presenc order recoup cost ha increas sharpli
japanes compani also say market share japan ha hit ceil
profit reach upward limit say fujisawa pharmaceut japan third largest sale bn
r expenditur ha doubl dure past year net sale increas onli per cent dure period
percentag r expens net sale rose
becaus typic drug take year bn develop onli compani larg enough absorb cost abl surviv long run
compani without strong r pipelin new innov product drift sideway say mr john wilson analyst jame capel tokyo
yamanouchi pharmaceut one aggress intern expans admit take anoth year befor compani becom truli global
fujisawa also increas product market capac us europ ahead launch fk immun system suppressor use prevent transplant patient reject new organ
japanes drug maker current boost effort build comprehens independ oper r product market
howev compar larg scale merger acquisit us europ purchas joint ventur modest size
mr thoma hofstaett execut manag director hoechst japan say lack candid acquisit japanes compani
mean sharp declin asset valu japan bought slump stock properti market made small medium size japanes drug compani ideal target global pharmaceut group look expand japan
countri market hold substanti potenti grow th popul age rapidli consum becom increasingli health consciou
corpor financi point smaller compani unabl surviv industri consolid due lack financi r resourc recept cross border merger acquisit
pfizer us drug chemic group announc plan buy koshin medic privat medic equip distributor earlier thi year
last year monsanto us acquir per cent hokuriku pharmaceut
merger acquisit among japanes compani includ rescu smaller compani also expect increas
mr john wilson jame capel predict allianc industri leader creat larger pharmaceut group would unlik due linger neg attitud toward among japanes compani
price continu big issu marjori shaffer examin develop us
us pharmaceut industri prosper mightili go go year
profit margin widen revenu grow th march steadili reliabl upward
one expect repeat perform mid continu pressur washington patient advocaci group insur compani slow rise prescript drug price
past decad industri habitu rais price prescript drug us least twice three time rate inflat
steep price increas contribut hefti doubl digit profit gain per cent
becaus pressur limit price increas analyst agre annual profit gain slow per cent
analyst even predict overal industri earn grow th could dip per cent
whatev number eventu turn heavi critic us prescript drug forc industri act restraint
pharmaceut giant merck said last year would rais price rate inflat compani includ pfizer bristol myer squibb follow suit
think less price flexibl past said spokesman warner lambert new jersey base drug compani ha announc price increas reason
pressur stem rise drug price appar take toll al readi area
earlier thi year drug compani report par first quarter result lead sell wall street
first quarter industri usual put annual price rais
thi year price increas halv per cent per cent typic past five year
analyst say continu price constraint hurt compani without strong product pipelin
upjohn drug compani base kalamazoo michigan mani analyst say lack strong research develop pipelin ha announc expect second quarter net incom flat
said wa offer voluntari retir per cent workforc reduc cost
bristol meyer squibb surpris wall street last month releas disappoint second quarter earn fore cast
price increas appar moder american still pay highest price world prescript drug
countri price subsidis govern negoti drug compani drug compani us long set price
elderli consum bear brunt cost accord studi purdu univers pharmaceut econom research center lay fayett indiana
purdu studi estim elderli account nearli per cent retail expenditur prescript drug us
cost prescript drug whelm burden peopl fix incom
senat david pryor chair senat special committe age critic prescript drug price
earlier thi year senat defeat bill propos senat pryor control pharmaceut price intend keep pressur
well publicis price newer drug underscor issu
may cancer expert criticis johnson johnson set high price drug levamisol treat colon cancer
compani set price dollar dollar year suppli time higher older version drug use veterinarian medicin
advoc mental ill attack swiss drug giant sandoz price ha set clozapin use treat schizophrenia
dollar drug plu requir weekli blood monitor
even befor experiment cancer drug taxol clinic trial advoc breast cancer patient wonder price drug may eventu reach dollar gram simpli reach women
pharmaceut industri ha long justifi price cite huge research develop cost
accord pharmaceut manufactur associ pma industri trade group washington research cost near dollar bn dollar
industri argu ha recoup r cost
us spend littl cent sale dollar r compar
cent cent industri said mr jeff trewhitt pma spokesman
cours nation price control like southern europ price lower said mr trewhitt ad countri price control littl biomed innov
jor world class drug origin us alon
thi innov ha foster free market atmospher
certainli r cost cover said mr trewhitt
despit industri protest drug price continu big issu accord analyst
stay veri difficult increas price three time whatev consum price index said mr neil sweig drug analyst capit institut servic
inde us pharmaceut industri brace colder busi climat analyst say near futur fill lower grow th rate lower share price
emphasi shift elderli alan archer assess threat profit
time world industri ha undergo restructur phase brought recess pharmaceut industri worldwid account former communist bloc reliabl sourc yet avail ha put forward defens qualiti ha live descript
industri execut ask themselv increas nervous much longer good time last
accord mr sam isali mehta isali new york world market grew per cent total sale dollar bn
industri annual grow th rate ha slow littl recent year continu exceed rate grow th world economi whole
past decad prove golden era pharmaceut industri despit rise sale industri still transit period highlight amount consolid take place past year
posit front mani industri feel underli demand innov drug meet sati fy medic need boost shift focu toward elderli
thi continu campaign run uk pharmaceut industri accord mr ben hay spokesman associ british pharmaceut industri abpi
use uk exampl drug expenditur per head age group four time level rest popul
compani benefit chang demograph pattern provid chronic diseas old age
arthriti coronari diseas hypertens central nervou system relat ill
mani compani invest heavili thi latter area particularli research alzheim parkinson diseas
compani come first product treat ailment would guarante spectacular sale well come ha aid treatment retrovir zidovudin
anoth import issu demograph chang impact demand
world popul grow rapidli per cent year poorest countri grow fastest
less develop region world account per cent popul present less per cent pharmaceut consumpt
mani industri observ believ thi rapidli chang next two decad
thought thi demand satisfi launch new product result new technolog molecular biolog produc larg quantiti new drug product base ration drug design
neg side mani cri industri fore cast reduc profit next decad
price pressur govern worldwid also privat buy organis
drug tempt target govern wish restrain soar health care cost although repres onli per cent health spend save money use sensibl
increas trend gener prescrib gener substitut mean product lose market share rapidli patent expiri
thi highlight fact tri test brand product tagament capoten tenormin includ new gener offer near futur
increas regulatori requir delay product launch caus eros patent life
mani countri regulatori depart backlog file await review
accord us pharmaceut manufactur associ recent estim cost involv develop new drug ha risen dollar dollar
sever year mani drug compani clear polici therapeut product group geograph area want trade take haphazard approach
pressur build onli compani clear strategi area want compet success ful
compani decid want year say mr robin gilbert analyst jame capel
certainli merck glax clearli defin role like upjohn warner lambert pfizer syntex complet clear posit
brought need much greater awar drug avail world drug market
gp much better choic medic prescrib increasingli use comput data base onli inform sourc also order pharmaceut
greater concern taken gener public action lobbi group media investig wherev possibl cost benefit safeti drug prescrib
increas collabor world wide regulatori bodi
globalis industri assist standardis regulatori approv procedur new drug
european regul unifi gradual come togeth us food drug administr fda
use fda european data investig glax file new migrain drug migran sumatriptan veri good exampl
launch uk octob drug ha fast track us approv fda may immin
grow knowledg compet compani r programm gener strategi
professor horst meyer head bayer pharmaceut think concentr world pharmaceut industri inevit
need substanti invest research develop requir discov block buster drug sale dollar year wa beyond mean largest compani
prof meyer said top compani spend per cent money dedic pharmaceut r proport wa like increas
addit smaller compani handicap inabl market drug three largest market us europ japan
top pharmaceut group abl recov ever larger invest sell drug three area ad prof meyer
author editor financi time pharmaceut busi news
shake way drug compani concern could forc negoti onli tradit hurdl safeti qualiti efficaci new one cost benefit
pharmaceut compani withstood recess though charm
appar inocul slow world economi sector ha offer conspicu impress earn grow th
part pharmaceut busi look sick prognosi group gloomi
incom grow th look set slow cost continu escal
face danger fall return sector look set signific restructur strong becom stronger weak driven merger even forc exit
main drive forc behind come shake increas state interfer drug price
govern everi tri control rapidli expand health care budget
age popul grow cost health technolog led alarm increas health care expenditur
per cent gnp per cent accord mr peter lauper head pharma econom ciba geigi swiss group
estim figur reach per cent end decad
govern agoni ha compound becaus burden increas ha fallen disproportion state
past year proport health care spend paid us feder state author ha risen per cent per cent
govern scare figur polit shi tackl expenditur hospit doctor see drug expenditur attract target cost save
govern attempt achiev save aggress pharmaceut price control
last month german govern extend refer price system set limit reimburs certain drug
japan financ ministri launch latest seri price cut last april
us polit pressur politician ha drawn blood
last month mr gerald mossinghoff presid us pharmaceut manufactur associ said drug compani suppli third us market promis voluntarili keep price increas rate inflat
price control start bite grow th world pharmaceut market deceler
well come british group estim world drug market increas averag per cent year
five year figur could fall onli per cent believ
forc drive chang rapidli rise cost research develop
us r expenditur wa dollar bn dollar
dr armin kessler presid european feder pharmaceut industri associ ha warn even exist level expenditur unsustain
thi context rise cost slow grow th pharmaceut group drug divis almost big chemic compani tri expand
industri cannot accommod warn mr david alcraft director health care pharmaceut pa consult group
uk exampl per cent drug market accord mr martyn postl consult cooper lybrand
slow revenu grow th increas cost industri return capit bound fall warn mr postl
compani previous abl offset lack new product increas price prove vulner
analyst believ us compani warner lambert upjohn highli depend price increas revenu grow th
first must creat innov product command premium price
must necessari market network exploit fulli
discov new chemic entiti fairli simpl
difficult part identifi one like provid competit advantag greater safeti efficaci
learn manag pipelin acceler develop select compound reach market quickli time remain ethic word cut corner
battl demonstr extent drug innov pharmaceut group ad new weapon armouri
order guarante premium price innov product drug group look demonstr cost benefit new compound
previous demonstr drug qualiti efficaci safeti
show cost effect say mr lauper
smith kline beecham tagamet glax zantac allow stomach ulcer treat home rather use expens potenti danger surgeri
howev concern drug compani could forc negoti onli tradit hurdl safeti qualiti efficaci new fourth cost benefit
danger regulatori author current onli concern safeti qualiti effici drug futur onli licenc medicin also demonstr save cost el se
drug group need access worldwid market forc maximis sale dure short period drug patent remain valid say mr postl
sever group abl increas revenu significantli set joint market agreement
well come exampl ha agreement market zovirax anti viral medicin hoechst germani sigma tau itali sumitomo japan
small compani abl surviv creat nich either research use new technolog market specif therapeut geograph area say mr alcraft
without suffici critic mass research develop compound littl experi negoti necessari regulatori hurdl
addit increas difficulti attract good research
problem medium size player emot difficult admit go next giant
option nich oper open tricki decis make
one solut smaller organis set joint ventur share cost market increas revenu offset massiv expenditur research develop
main synergi appear market reach extend cost save achiev rationalis headquart cost
mani pharmaceut compani part larger chemic group
short term main board unwil give high perform pharmaceut divis
long term pharmaceut group must gain critic mass find nich area specialis wither
pharmaceut laboratori come mani shape size
grandest pound research centr construct glax stevenag mile north london
glax lab said largest build project uk channel tunnel hous research open
mani scientist work togeth one site give access best possibl rang expens date equip
danger howev bureaucraci smother imagin approach essenti develop innov drug
glax tri overcom thi clever research manag make scientist feel work small unit
opposit school thought research flourish best genuin small group illustr scotia pharmaceut emerg uk compani specialis drug base essenti fatti acid
yet carri research develop six wide separ site
callanish isl lewi outer hebrid dunde east coast scotland carlisl north west england writtl essex guildford surrey nova scotia canada
dr iain law charg r callanish sure remot pharmaceut laboratori europ say keep good touch facil visit colleagu weekli note written scotia r manag circul around compani
pharmaceut lab whatev size locat face common challeng
restrain soar cost r time speed discoveri develop new drug
accord data collect centr medicin research uk worldwid spend pharmaceut r increas averag per cent year dure
almost half industri r expenditur europ per cent us per cent japan
unfortun rapid rise r spend ha produc correspond increas flow new drug onto market
number medicin launch dure earli averag per year
dure three year wa close year
number new drug origin europ ha fallen decad year year
total time taken develop new drug ha increas steadili sinc
clinic phase test drug human patient doubl dure reach averag seven year
trial take longer becaus regulatori author requir clinic data doctor patient becom reluct take part
compani spend time money recruit hundr even thou peopl requir test drug
lobbi author reduc regulatori burden oper r effort effici
one way eas regulatori burden harmonis requir around world compani repeat test unnecessarili sati fy author differ countri
thi al readi happen within europ ec
global level first intern confer harmonis brussel last novemb wa import step toward bring us japan europ line
wa agre exampl routin month toxic test anim abandon favour six month studi
much need done particularli harmonis clinic requir
complet standardis unattain becaus medic practic social condit vari much around world
ultim object retain onli differ justifi ration criteria
time compani tri improv product research particularli pre clinic phase control close clinic trial
invest heavili new technolog rang computeris chemic databas molecular model graphic automat gene sequenc machin help scientist select adapt compound rapidli drug develop
besid introduc new technolog industri chang way manag r
redesign approach get fastest possibl answer question
say dr tom mckillop technic director
ici consist achiev target administ candid drug human volunt within month first synthesi great improv compani previou averag perform month
time ici much ruthless abandon compound live initi promis
dr mckillop say new regim quit differ ici tradit approach assum everi drug wa go succeed
british bio technolog loss doubl pound
british bio technolog recent float pharmaceut group yesterday report loss befor tax year end april almost doubl pound
mr keith mccullagh chief execut said result line expect
product research develop expenditur wa like increas pound
thi would lead loss per cent higher current year
net cash flow wa pound pound partli becaus increas spend
mr mccullagh said thi follow decis push research develop stage allow compani gener substanti revenu later date
balanc sheet remain strong cash reserv pound year end said
thi increas pound follow flotat would allow group extend clinic trial programm
mr mccullagh said group strategi wa sell market right medicin would prescrib gener practition keep uk possibl european right product sold hospit
drug requir smaller less expens sale forc
british bio technolog would look sign co develop market deal late thi year earli next year signific pharmaceut compani aid vaccin
drug ha complet phase safeti trial healthi volunt group hope establish efficaci trial
pharmaceut divis enter flat period decad success
ici bioscienc demerg thi year would account per cent group sale per cent profit research spend
ici bio take fast grow scienc base busi prop ici fortun dure recess last two year
intern compani closest shape ici bio ciba geigi switzerland also domin larg profit pharmaceut busi larg less profit agrochem busi scatter smaller specialist chemic activ
monsanto us sandoz switzerland intern chemic group biolog orient similar ici bio
pharmaceut divis wa ici success ful oper last decad
ha onli share gener prosper intern drug industri also contribut best seller particularli treat heart diseas cancer
howev analyst believ current rapid grow th ici pharmaceut
inde half yearli result announc yesterday show drug sale profit onli margin
best mr ronni hampel ici chief oper offic could say wa
continu expect pharmaceut perform whole year level approach last year
pharmaceut sale suffer expiri last year us patent protect tenormin ici best sell heart drug
al readi per cent tenormin prescript replac cheaper gener version atenolol
ici least expect lose tenormin revenu
thi year unexpect blow wa drawal becaus side effect tema floxacin antibiot compani licens abbott us order fill gap product line
posit side sale ici three ne west drug zestril heart zoladex cancer diprivan anaesthet third thi year
dr tom mckillop technic director ici pharmaceut say compani ha veri strong portfolio drug variou stage develop clinic trial
could give ici pharmaceut new burst grow th late rel flat period
howev success ful new drug ici bio may find difficult keep pharmaceut busi run independ medium size player increasingli competit global industri
ici onli number world leagu drug compani term sale
analyst predict link competitor merger acquisit comprehens global allianc order maintain strength research develop market
last year wa specul ici well come combin would make strateg sens recent well come share sale propos demerg ici bio would make thi easier
although restructur agenda intern pharmaceut busi urgent prioriti agrochem industri ici world second largest player ciba geigi
curb agricultur product especi europ reduc sale farm chemic lead overcapac
ici agrochem ha strong scientif market base prospect look bright
ici seed still much smaller busi agrochem ha better grow th prospect
compani develop rang genet engin seed crop rang non squashi tomato herbicid resist corn
promis ici bio busi includ quorn fungal food biopol biodegrad plastic made bacteria
ft sep smith kline plan r shake
group cut job invest new facil end research gastro intestin drug
smi thk line beecham anglo us pharmaceut group make far reach chang research develop
involv redund among uk research staff pound invest new r facil surprisingli drawal long term research gastro intestin drug field provid best sell product ulcer medicin tagamet
strateg realign r final phase cost cut rationalis follow merger beecham uk smith kline beckman us
save manufactur market administr al readi cut group workforc help rais pre tax profit per cent year
resourc must focus drug discoveri highest potenti return said dr georg post r chairman
result sb ha decid discontinu sever research programm
strike casualti gastro intestin drug discoveri led tagamet sale exceed dollar bn pound past six year recent kytril anti nausea drug launch last year competitor glax zofran
feel basic research thi area ha proceed slowli difficult identifi ration candid drug discoveri said dr post
emphasis develop work sb exist gastro intestin compound would continu
realign leav sb drug discoveri programm five area
uk r site cut eight six
sb close medic offic reigat surrey small research facil antibiot factori worth sussex
redund includ scientist technician offic staff spread across eight site
pound invest new build equip next four year concentr brockham park great burgh surrey mundel hertfordshir
sb continu divid r effort equal uk us
dr post said sb plan devot per cent pharmaceut sale r
molecul muscl look faster method get drug market
visit biotechnolog pharmaceut compani day may yield surpris casual observ
lab complet test tube scientist goggl white coat still
increasingli promin though comput room research sit dark look colour pictur screen design drug futur
new molecular design method becom increasingli signific industri year account mani new drug market said jaquelin siegel industri analyst hambrecht quist new york
new method sometim refer second gener biotech realli converg biotechnolog convent molecular design
biotech industri tradit product protein use ful applic ha discov
problem use protein drug big get biolog barrier bodi
simpli larg explain joshua boger chief execut offic boston base vertex pharmaceut
size mean must inject straight blood
insulin consid first biotech product one smallest protein exist ha molecular weight compar aspirin ha weight
thi particular problem becaus greatest medic challeng scientist fight diseas like cancer aid
biotech product big taken oral want treat chronic diseas requir continu administr realli need oral product boger said
scientist agre industri familiar protein structur invalu search use ful drug
new second gener techniqu requir chang philosophi industri
new methodolog protein longer thought possibl product
realis mani chronic diseas caus reaction singl protein within bodi said john maraganor head biolog research boston base biogen
design molecul bind protein somehow affect reaction may use ful drug
vertex use new method work cure aid caus hiv viru
compani ha discov empti space protein chemic process caus viru becom activ
hope plug space molecul would simpli lay dormant bodi
product probabl come market first one develop tradit pharmaceut group merck prevent glaucoma
late clinic trial product may pharmaci shelv earli
squibb hoffmann la roch also use second gener molecular design techniqu come new drug
second gener power approach heavili utilis industri said peter lomedico senior director molecular biolog hoffmann la roch
tradit pharmaceut compani approach new techniqu differ direct biotechnolog firm
unlik biotechnolog compani pharmaceut group alway busi look small molecul
problem wa wa littl method mad
old fashion research method call year random test said boger work mani year pharmaceut industri
often use soil sampl becaus contain mani differ compound
tradit drug discoveri take averag seven year
averag cost tradit drug develop hefti dollar pound per product
trial error much error said boger
aim second gener biotech get drug market faster
new techniqu lot better tradit grind find approach said siegel
anoth problem tradit drug develop creat product often ha side effect
compound may cleav protein want may bind protein well said boger
new molecular design method tri get specif possibl tri come molecul bind one specif protein
whatev direct come biotechnolog pharmaceut compani use similar method new molecular design approach
latest techniqu take advantag process call x ray crystallographi enabl research take three dimension pictur protein
protein enter comput screen scientist design drug believ react target molecul
thi method sometim refer structur ration drug design
becom increasingli like recip explain maraganor
want make compound longer fit protein better add mino acid shorter take bead
come someth found natur would tradit biotech product uniqu design drug bind specif protein
structur ration drug design use protein expertis biotechnolog firm molecular design method pharmaceut group
reason mani compani find joint project best road take
develop thi new techniqu use expertis industri inspir lot partnership form biotechnolog pharmaceut group said siegel
latest method drug research begin take hold industri product develop techniqu yet avail market
thi perman trend industri said lomedico hoffmann la roch
price constraint threaten undermin sale earn lead drug compani
prospect victori governor bill clinton us presidenti elect ha hit us pharmaceut stock
sinc democrat convent juli share market favourit last year fallen per cent averag
sharp declin ha prompt fear clinton administr might introduc control drug price follow lead countri
ministri health nearli largest market plan measur slow grow th drug spend price cut freez
pressur threaten undermin sale earn grow th lead eventu restructur world pharmaceut industri
august first time germani krankenkassen health insur organis provid cover everyon work slash amount pay drug cut price averag per cent
reduct follow two year price freez part packag observ believ could slice drug group profit germani world third largest market pharmaceut quarter
itali world fourth largest market treasuri set drug price ha refus allow ani increas
mean japan world second largest market ministri health ha cut drug price per cent averag thi year
price medicin reduc nine time past year
us world biggest market pharmaceut one last denmark drug price set govern implic price curb could seriou
compani al readi voluntarili limit price hope avoid legisl effort may late prevent
reason worldwid pressur price health care budget almost everi develop countri control
combin rise demand care age popul increasingli expens medic technolog ha sent health spend spiral
germani spent per cent gross nation product health care compar per cent
last month german health ministri warn krankenkassen could regist deficit western germani alon dm bn pound bn thi year becaus cost health care would outstrip contribut
us health care expenditur ha risen per cent gnp per cent
period proport cost met feder state author ha increas per cent per cent
rest paid individu privat health insur
govern face rise health care expenditur prefer target price volum drug prescrib rather trim spend polit sensit area hospit doctor
dilemma particularli acut us american congressmen threaten industri legisl follow public august report us gener account offic investig arm congress
report show price drug see accompani chart increas per cent past six year compar overal rise consum price index
congressman pete stark californian democrat chairman hous way mean health subcommitte said report demonstr wa justif steep price increas prescript drug
drug compani use monopoli statu make kill veri sick peopl said report public
mr paul freiman chairman us pharmaceut manufactur associ say war word price partli reason whi relat govern american pharmaceut sector lowest point year
respons global drug group ha defens
argu set sight price govern aim wrong target
expand health care budget drug driven phenomenon
uk proport health expenditur repres drug ha onli risen per cent per cent say mr jim attridg intern busi oper manag ici pharmaceut divis
expenditur drug account per cent total us health care cost accord mr peter lauper head pharma econom ciba geigi switzerland
last year proport wa per cent although overal spend drug wa
period much rise health care spend wa gener cost run hospit doctor surgeri
mr lauper say expenditur hospit staff cost repres per cent health care spend us reach per cent
nevertheless drug compani admit case help tradit high profit margin return capit
glax worldwid pre tax profit margin
per cent last year smith kline beecham anglo american health care consum product compani
merck us giant world largest drug group margin last year
dure fatter year late pre tax margin attract littl attent
industri earn plung dure current recess pharmaceut group conspicu strength
industri defend profit argu need invest research develop
american group exampl spend dollar bn year research bring new drug market compar dollar
mani diseas still cure rang aid alzheim
given adequ resourc industri claim find
per cent medicin discoveri develop drug industri accord us pharmaceut manufactur associ
american compani discov top sell drug launch
countri lower price profit margin franc develop best sell medicin becaus earn enough plough r us industri alleg
one snag thi argument industri high margin calcul cost r deduct
word substanti profit achiev industri bank compani met r expens
spend much r profit would greater
american politician far unimpress voluntari undertak industri control price
merck upjohn hoechst roussel bristol myer squibb ici pfizer introduc measur hold price
far compani suppli third us market promis keep price rise line consum price index accord industri associ
spite undertak global pressur price unlik disappear
ensu structur chang accord mr viren mehta partner mehta isalay new york health care invest group produc bifurc industri
accord mr mehta compani develop depart expertis scale necessari bring drug market quickli us europ japan
also strong market skill exploit new medicin full
among list merck pfizer us glax uk
weaker group use gener profit grow th price increas particularli hard hit recent price constraint
third quarter thi year exampl us group bristol myer squibb report pre tax profit grow th per cent upjohn increas wa onli
contrast merck one increas earn per cent
polaris industri could follow consolid among
mr martyn postl pharmaceut industri consult cooper lybrand manag consult group say
top compani per cent world pharmaceut sale
end decad top group control half market
economi scale among lead group would allow reduc proport turnov spent market r
mr paul krikler industri analyst goldman sach stockbrok say lead compani could reduc sale gener administr cost per cent turnov glax current spend per cent turnov sale administr
cost could save rationalis pharmaceut manufactur area signific capac
drug group duplic manufactur plant particularli european countri use promis local invest negoti higher drug price govern
glax ha manufactur capac site countri
cost cut ha al readi start
last week eli lilli said wa spend dollar
syntex us group also announc restructur plan dure week
cost contain larger group may becom stronger global competitor
weaker compani trend toward govern impos price constraint world main market threaten surviv
pressur e price percentag wholesal price rise six year tenormin hypertens ici
du pont merck consum price indic item
tighter lid pillbox drug compani toughen approach research develop
drug industri adopt increasingli ruthless attitud research develop spend grew fourfold past decad reach estim dollar bn pound
compani work reduc interv drug discoveri market averag year time control soar cost r
strike exampl hard decis made wa thi autumn announc smith kline beecham anglo us group redund among uk r staff
equal shock peopl insid outsid compani wa drawal long term research gastro intestin drug field led best sell product ulcer medicin tagamet
georg post sb new chairman pharmaceut r said today climat resourc must focus drug discoveri highest potenti return
wa worth continu search new gastro intestin drug becaus better target field
post also state sb intent hold r budget per cent pharmaceut sale
similar r commit intern drug compani base europ us
roch switzerland stand larg r spend equival per cent prescript drug sale
tabl show roch less match two giant industri glax uk merck us total spend r dollar bn
research expens except high switzerland roch doe employ larg r workforc
extrem compani base uk scientif salari notori low afford employ peopl dollar spent r
forc pace develop compani set increasingli tight timet stage r accompani tough criteria everi project must sati fy move next stage
exampl ici pharmaceut uk consist achiev target administ candid drug human volunt within month first synthesi say tom mckillop technic director
thi stage use take averag month
time ici ha becom determin abandon drug live initi promis
new approach quit differ compani tradit attitud assum everi drug wa go succeed mckillop say
strong manag requir kill promis research project face lobbi scientist devot year work still believ would lead blockbust drug onli compani would let continu littl longer
max gurtner head corpor commun roch put manag develop pipelin realli tough becaus deal peopl feel live die project
comprehens survey r manag intern pharmaceut industri publish thi year uk base centr medicin research show half compani target maximum time take new drug discoveri first market
thi averag eight nine year us european compani year japanes compani
detail analysi research project pa consult uk suggest two largest pharmaceut compani succeed get drug market faster competitor
averag time market eight intern compani wa
speed partli result clear sight manag
pick winner set prioriti prevent anyth els distract clutter system said richard syke glax research director
size may advantag becaus giant drug develop ani one time therefor flexibl concentr promis candid
exampl way glax switch chemic research resourc thi year develop promis aid drug tc
noth allow stand way said grahaem brown charg develop programm
giant also afford take risk smaller compani parallel develop move next phase project befor complet current one
pharmaceut compani japan tend proceed cautious prefer carri r step step rather parallel stuart walker director centr medicin research point
result japanes drug take even longer reach market western one fewer drop dure develop process
japanes drug compani yet spend much r european us counterpart r budget typic amount onli per cent sale
go increas spend come line rest world want becom jor global player walker say
onc drug compani put right manag place research call enorm rang new technolog help
comput use everi aspect pharmaceut r graphic system design new molecul inform system keep track immens volum patient data amass dure clinic trial
exampl start drug discoveri process glax core collect compound chosen comput chemic analysi give repres sampl molecul known scienc
idea wa come divers possibl select molecular structur
glax research want develop medicin particular target start screen core chemic discov ha biolog activ want
thi give lead compound improv help molecular graphic comput produc one candid drug
may even opportun use inform technolog later r process acceler clinic trial usual take half total time taken get drug market
merck clin net project show compani benefit comput network link headquart clinic centr around world
clin net instal last four year allow manag follow progress thou patient far effect unwieldi mixtur mail telephon call fax use previous
exampl network enabl merck analys earli clinic result proscar new prostat drug came make quick judgment wa worth wait month data befor submit licens applic becaus would provid persuas evid medicin efficaci six month data
progress scienc particularli genet molecular biolog ha given pharmaceut industri possibl avenu research ever befor
one sens thi golden age drug develop
pharmaceut manufactur al readi devot higher proport revenu r high technolog industri electron aerospac
face like squeez profit next year govern tighten price control
rise r spend long sourc pride drug compani could soon becom embarrass
world top pharmaceut research compani r r r manpow expenditur sale pound glax merck smith kline beecham hoechst ciba geigi bristol myer squibb roch eli lilli sanofi winthrop well come boehring ingel im rhone poulenc rorer ici sandoz sourc
pfizer one fastest grow us drug group increas annual research develop spend dollar bn next year
mr henri mckinnel chief financi offic said aim wa increas percentag group sale pharmaceut
dure first nine month thi year drug gener per cent dollar
bn sale compar per cent last year
mr mckinnel said group would limit price rise us prescript drug per cent per cent come year
announc follow grow polit pressur congress limit price increas
number group includ merck largest us drug compani undertaken rais price least limit rate inflat
promis increas invest research develop per cent next year follow per cent rise dollar
invest design help group counter expiri patent
patent improv robert rice explain chang ec regul affect commun pharmaceut industri
look like happi new year europ pharmaceut industri
januari year wrangl intens lobbi european commun adopt regul grant five year extra patent protect drug
extens effect period market exclus drug system supplementari protect certif spc design give pharmaceut compani fair return grow cost research develop new drug prevent research work move ec us japan drug al readi enjoy extend patent protect
legisl born polit compromis howev european spc system far straight forward
extent differ ec state alter effect regul way implement threaten bureaucrat administr night mare
gener produc compani make patent drug licenc face period uncertainti
long time ha wide pread concern necessari safeti test new drug impos heavi penalti pharmaceut invent compar sector technolog
patent europ gener last maximum year applic date
accord ms patricia harri intellectu properti lawyer citi solicitor lovel white durrant develop period new drug discoveri market authoris last averag year
complex area research diseas current regard incur alzheim motor neuron diseas multipl sclerosi develop time may even longer
thi mean time obtain approv market drug compani littl patent term left use monopoli right recoup increasingli heavi cost research develop say
although ha littl evid research migrat us japan patent protect longer abandon european govern accept would fool hardi wait sign declin ec pharmaceut industri befor take action
consum organis howev warn extend patent protect could push overal drug bill public health servic across europ restrict market gener product
govern recognis far push overal drug bill extend protect could use drive pharmaceut price say mr martin paltnoi pharmaceut market consult
thi becaus onc reason period market exclus guarante rational allow drug compani charg high price recoup develop cost uncertain short period patent cover longer exist
avail length drug develop period minu five year maximum five year
develop period defin time file patent ec countri spc sought date first authoris use ec whole
ms harri say thi mean develop period five year less supplementari protect avail
develop period five year spc five year avail develop period year full five year spc appli
separ applic made patent offic member state supplementari protect requir
applic file within six month drug authoris use relev countri
drug al readi patent authoris relev member state januari transit provis appli ani applic spc must file juli
transit provis spc product must gener first authoris use ec januari
howev belgium itali germani denmark adopt differ date transit provis appli greec portug spain regul come forc
complic matter spanish govern ha start proceed european court regul set asid
chang mean administr headach nation patent agenc mr paltnoi believ struggl find ec drug wa first authoris use order calcul length spc
without pool intern data accur verif first authoris may prove imposs mani case warn
ms harri warn uncertain period compani produc patent drug licenc
licenc usual express last durat patent
spc doe extend patent simpli grant addit protect
license want continu exclus licenc produc market drug spc renegoti licenc agreement
spc go way toward meet industri requir adequ period patent protect europ say ms harri
also watch interest industri agrochem also experi problem recoup r cost becaus length time take obtain market authoris
ft apr survey pharmaceut research develop
select process critic winner loser decid
develop crucial compon futur fortun pharmaceut group
access either intern extern excit research
way compani select new chemic entiti way develop decid sector winner loser
differenti come way select research use creativ flexibl way explain dr rolf kreb chairman boehring ingel im
select compound far easi yet accord dr richard syke glax chief execut director r thi critic decis made
drug must potenti import medicin signific advantag term safeti efficaci say dr syke
r director agre ani compound must innov success ful
industri doe gener enough innov product end fight cheap gener product say dr kreb
defin let alon gener innov product easi howev
problem know go el se say dr georg post r chairman smith kline beecham
take tagamet anti ulcer product sale dollar bn year
new chemic entiti like black box say dr post
might behind three compani opposit second third compound could fall waysid explain
onli gener compound set drug say dr post
ha wrongli becom pejor term say dr leon rosenberg presid bristol myer squibb pharmaceut research institut
giant step onli made onc decad even everi year
world two top sell drug zantac vasotec compound dose safeti improv
dr post agre point compound given classif us food drug administr actual offer improv safeti toler qualiti life better dose earlier medicin
molecul take longer develop heighten danger cut reason safeti efficaci
dr max wilhelm ciba say develop portfolio must balanc follow product case fail
must also good mixtur safe bet high risk high reward product
onli develop product reach annual sale
sometim innov justifi say dr wilhelm
explain hi recent decis launch lotensin ace inhibitor hypertens even though market satur even price competit us
argu develop drug gave compani access expert opinion former
without lotensin ciba credibl cardiovascular market would undermin
kept us market place scientif commun make money say dr wilhelm
dr frank joachim morich director pharmaceut r bayer say pleas hi compani fail figur among top group list order number compound develop
say relationship number compound develop innov
dr jurgen drew presid intern r roch ha also becom increasingli tough
becom veri vigor refus develop agent innov profil
cut number compound develop per cent past month
dr drew say increasingli larg proport molecul propos research reject
reckon year ago onli per cent compound enter clinic develop made market
barrier higher proport reach market per cent
fewer higher qualiti less attrit say
ad complic develop process need conduct intern
spite effort harmonis regul author us japan europ still often requir differ clinic trial
given cost bring drug market pharmaceut group must develop medicin three region cover per cent world market
begin licens product co develop turn contract research organis bessalaar pharmaco us munich base harrison clinic research conduct clinic trial
given increas demand regulatori group group look cut number studi complex studi conduct
seduct conduct trial add supplementari question realli necessari creat enorm quantiti data analys say dr stephen hill medic director roch product roch uk subsidiari
r director must also brutal cut project say dr syke glax
compani ahead drug good need act
noth wrong cut project decis made
final end product good read say dr drew
new drug applic must attract dossier must entertain valu
read faster becaus investig becom involv posit way claim
ft apr survey pharmaceut research develop
time cost fortun speed essenti bring drug market
reduc time take bring drug market ha becom pharmaceut industri overrid object
urgent immedi issu concern industri ha time market say dr jurgen drew presid intern r roch
two main reason shorter develop time
first want help unmet medic need public tri serv say dr leon rosenberg presid bristol myer squibb pharmaceut research institut
second reason limit period drug protect patent
anyth pick time mean million dollar sale say
rule thumb drug develop everi day drug held back market cost drug compani dollar explain mr david matheson senior vice presid boston consult group
dr willi stammberg head develop hoechst estim one month delay launch import new product result cumul sale loss dm dollar
add cost develop bill reduc revenu end product patent life
speed market also offer competit advantag
dr georg post chairman r smith kline beecham point matter good compound speed essenti
point five year behind competitor product
fair say speed market wa primari reason success dure say mr bob easton presid wilkerson group new york base consult
coincid two fastest compani glax merck also world biggest pharmaceut group
group agre need acceler drug develop perform mani group continu disappoint
still tremend variabl perform differ compani say mr matheson fastest conduct phase two phase three studi three time quicker slowest
take eight year littl two half year
mani research develop director justifi length time take develop drug point far difficult prove safeti efficaci therapeut area indic
exampl becom clear within coupl week whether antibiot work wherea central nervou system product take year
take ht say dr richard syke chief execut head r glax
zofran emesi wa easi either feel sick
anxieti depress ordementia much subject whether work
mani r director claim problem compar appl orang
slower becaus portfolio ha difficult drug say mr matheson boston consult group
huge differ perform within therapeut area accord mr georg farrington head pharmaceut wilkerson group
antibiot exampl best compani develop medicin month compar month worst
one key area drug group improv manag portfolio
match resourc portfolio avail ruthless drug take develop say dr tom mckillop research technolog director zeneca
run compound simultan decid one bet
mani compani tri run mani candid pipelin slow develop
dr rosenberg bristol myer squibb agre resourc alway finit
compound late stage develop need best clinic trial offer say
schere prof gunter stock board director charg r say master plan agre start project
key compound acceler develop must held lack resourc
correct mix product within portfolio also essenti say mr matheson
group must balanc familiar new area
area familiar compani know regul understand requir end point clinic studi
new therapeut area develop scientist leap fenc first time
must also balanc risk within portfolio especi phase one trial likelihood compound drop higher
balanc obtain necessari data registr make dossier complic
integr team pharma economist clinic develop process cost effect drug incorpor regulatori dossier
must ensur adequ suppli compound readi clinic trial
mani group take risk manufactur larg quantiti befor end pre clinic develop
start pivot studi usual longest largest soon possibl ensur design right
manag dozen investig around world necessari trial
clear averag scientist bench much money lose delay project
cope effect paper mountain build clinic trial
howev dr drew roch warn ru hing product market panacea
bring product market ani qualiti quickli possibl onli make sens someth worth
point develop someth speed light trivial
ft apr survey pharmaceut research develop
work togeth creat new product research develop market depart need focu resourc
research develop cost increas need focu resourc becom ever greater
r depart must join market depart match scientif expertis market opportun said dr trevor jone well come director research develop medic uk
market pressur world pharmaceut compani find effect new drug increas
accord us pharmaceut manufactur associ us industri spend dollar
achiev per cent return invest minimum compani might expect given risk per cent per annum compound grow th sale current dollar bn demand downward price pressur
compani like long term winner increasingli aggress competit r environ effect r manag make full use new technolog discov new compound utilis skill market depart earli stage concept idea
one compani well come believ success pharmaceut compani depend fundament qualiti r market activ interact synergi
three phase involv develop product accord dr jone requir good commerci input thi becom quantifi import phase progress
good exampl market r work togeth lipoxygenas inhibitor said dr jone
lipoxygenas pathway gener respons inflammatori disord known involv inflamm whether inflammatori bowel asthm allerg rhiniti psoriasi arthriti
dr jone question focu product inflammatori condit drug work earli stage want market depart focu attent area like one go becaus otherwis shotgun therapi
need someon work agre togeth focu beyond discoveri first phase said
asthm becaus big pathway first task go volunt see work
need market depart give design busi case becaus go start spend pound pound
goal chang consider past five year said dr jone
drug go make well come pound year three go
dr rolf kreb chairman boehring ingel im former head bayer r said
boehring ingel im ha problem choos compound
current process set test properli function develop process
peopl formerli fear go small market
make look market develop differ way
dr kreb point total cost dollar includ failur divid success ful
realis compet highli competit market need high therapeut standard need far market
take three nine year establish drug
lower therapeut standard complet new product need less market
may well allow profit nich market
chang technolog open nich market new drug thi may accept futur
indic high therapeut benefit get higher price lower promot cost
boehring ingel im futur look medic properti compound decid area interest may wide rang compound
told market peopl thi could happen
organis themselv becaus market longer stabl function said dr kreb
view taken ciba geigi work onli area unmet medic need room improv intern know
dr max wilhelm pierr douaz head pharmaceut ciba said
target fr five year ani drug question develop
said figur us dollar otherwis licens product especi product aim gener practition would stretch market resourc
astra therapeut area chosen said dr clae wilhelmsson execut vice presid r
three year ago compani wa cancer isinto
immuno suppressor taken respiratori field cancer
look medicin therapeut need tri develop complet new idea rather compound
exampl develop ace inhibitor licens one hoechst said
alan archer editor financi time pharmaceut busi news
glax world biggest spender pharmaceut research develop reorganis r
compani spent pound r last financi year intend spend pound thi year ha split posit r director
sir mark richmond chairman uk scienc engin research council becom director research divis period two year
serc largest britain govern fund research council
distribut pound year grant univers scientist engin
goran ando current research develop director becom director group develop product strategi
ando sir mark report richard syke chief execut board director respons r
syke say rapidli expand knowledg base especi understand genet basi diseas microbiolog cell mean pharmaceut compani would increasingli access inform univers biotechnolog group
access research realli critic futur compani need veri good peopl
sir mark ha except scientif skill hi experi molecular genet edinburgh univers microbi biolog bristol univers
also ha organis skill run serc vice chancellor manchest univers largest outsid london
sir mark respons research glax research organis move new headquart stevenag
syke say ando posit wa also highli critic
would respons develop safe effect medicin repres signific advanc therapi
head product strategi would ensur import link product develop market tighten
ft oct smith kline move research staff
smi thk line beecham second biggest drug compani britain spend pound consolid research develop centr
compani said yesterday job would lost peopl would ask reloc
smith kline buy acr site bp maritim centr harlow essex next one exist research centr
thi enabl stop research four seven centr brockham park great burgh reigat surrey worth sussex
research headquart move great burgh harlow
signific cost save reduct oper cost maintain fewer site
mile year site peopl singl site would improv interact effici
acquisit also provid enough land eventu consolid uk pharmaceut r one locat desir
pound capit cost scheme cost reloc al readi account compani provis restructur research side
smith kline plan come drug sector increas pressur cut price govern anxiou reduc health spend
compani conced might offer redund object reduc number
reigat centr close next year leas run
non research staff move third quarter next year
harlow tonbridg kent welwyn garden citi hertfordshir
like mani big pharmaceut group sandoz switzerland ha live night mare discov drug new categori see anoth compani bring competitor compound market first
one reason whi ha split develop depart away research activ
britain glax announc similar move last year
onc decid develop product go full
room half measur say ur barloch chief execut sandoz
reason chang come research side rapid advanc biochemistri chang natur research manag
past pharmaceut research wa chemic base proceed rel gentl pace
rise biochemistri ha becom fast move
pharmaceut compani recognis speed advanc biotechnolog make imposs keep hous laboratori speed front
consequ tend set co oper arrang independ biotechnolog laboratori start compani
sandoz ha arrang consum tenth fr
bn pound r budget barloch convinc number rise
yet good feel right balanc trend increas say
point ha alway difficult find research manag skill requir much greater
need someon know happen basic research find lead new compound
ha abl decid quickli co oper deal enter one keep
assum person found argu much k look develop well
ani event believ manag develop involv test discoveri point put market demand differ skill research manag
run way veri similar product centr
sandoz ha notori slow develop depart past
year ago brought manag consult mckinsey tri speed process last year set project team approach
still feel among veri best barloch admit confid catch
want give full respons head differ section reduc matrix minimum
develop far expens part r process especi clinic studi
thu group believ must concentr research effort find call number one compound clearli ahead competit
even fast develop depart becom difficult catch barloch say
delay cut stroke pen comput stylu could shorten trial period pharmaceut compani
delay get blockbust compound market give rival time launch price cut imit
day hold cost drug compani dollar pound lost revenu
result race bring latest comput technolog cut approv time
clinic trial particular target big pharmaceut compani
mani big drug compani invest person comput facsimil machin rhone poulenc rorer us ha gone one step
conduct trial pen comput electron tablet reminisc victorian school slate stylu pen use write screen
softwar usual display form box tick fill
eventu pen base machin could obviat mountain paperwork associ drug trial
case record form complet triplic cm thick one patient
typic trial would involv three phase averag patient per trial
rhone poulenc rorer part rhone poulenc franc use pen comput trial antibiot began last decemb
site involv eight use pen comput duplic paper system
aim say greg fromel associ director clinic research us assess much quicker electron system could
fromel see two big area time save
first data entri transfer paper base test result comput alway bottleneck
data often type two three time introduc error delay
pen comput inform enter screen transfer directli main databas
second research lose month correct basic error paper data
softwar select rhone poulenc rorer german compani padcom help elimin
number requir respons specif question softwar allow doctor enter letter tick
softwar check birth date patient ensur appropri age take part studi queri inform appear outsid like boundari unlik paper questionnair
although fromel believ breakthrough ha creation comput take handwritten inform compani grid ncr tandi ibm us nec toshiba japan argu hardwar provid competit edg drug trial softwar
casella hoechst subsidiari frank furt clinic project manag dieter r
dannhorn believ critic softwar guid doctor mani inexperienc use comput form
need doctor happi system otherwis go get ani patient trial
casella ha al readi conduct short clinic trial pen comput patient plan clinic trial anti fungal product involv patient centr patient question three time
doctor involv receiv diskett complet patient visit
rhone poulenc rorer trial diskett also use record patient inform
post central offic data enter databas
futur data could sent automat phone line
drug compani believ earli predict potenti save padcom director market peter munzel calcul typic phase ii trial drug test efficaci first time save could per cent
centr patient involv month period patient visit doctor six time munzel calcul save dollar total studi cost dollar reduc number queri need retyp
argu pen comput use throughout drug approv procedur could cut month studi
averag studi per drug could cut month even year eight year usual take get drug approv give compani extra two three year sale compound befor competitor flood market
challeng make jor improv whole host area say mark delfino manag specialis inform technolog boston consult group chicago
pen base system per se onli friendli interfac easier way get data
onc data come still need set process handl quickli
although pen comput save time data entri dannhorn calcul unfamiliar write case studi book pen pc mean take five time long write one pen comput doe paper base trial
drug compani could drawn write much softwar need set expens centr technic expertis add delfino
reckon cost dollar dollar per site equip trial site machin
today pen comput often rel heavi short batteri life
far de facto oper system compani favour develop silicon valley start go
pharmaceut compani quick adopt pen comput strong reserv
one concern handwrit recognit technolog still rel primit
doctor notori bad handwrit say stephen hill uk medic director roch swiss pharmaceut compani
fear data could inaccur record particularli intern trial conduct english english first languag doctor involv
one biggest problem make sure inform collect match inform patient record continu hill
data enter directli pc doctor surgeri compani main databas without intermediari check mistak could slip
regulatori issu also hamper wide pread take system
pfizer uk oper sandwich kent exampl research still wait pronounc us food drug administr use electron signatur
paper trial investig doctor ha sign trial result valid guidelin electron signatur
although inform casella trial record screen german law requir result trial print sign doctor trial valid
glax uk research experi pen base comput believ anoth two three year befor reli utterli
say spokesman glax voic recognit technolog doctor simpli talk machin could made similar advanc might becom domin technolog
thorough prepar cut cost manufactur product save year develop could equival final year sale
lead compound could dollar clinic trial
industri oper stringent regulatori control pharmaceut industri
complex volum regul indic high cost area one clinic trial expens time consum
three phase clinic research longest costli stage develop new drug
take averag four six year although depend type drug may extrem case requir year
singl advanc effici commerci scientif benefici
consider data assembl trial subject detail statist evalu medic interpret
effect inform technolog manag competit aid cut high cost help streamlin product develop approv process
compani cannot take short cut clinic trial well plan risk error document test greatli reduc
today increas number world lead pharmaceut compani look contract research organis cro run part case whole packag clinic trial
dr john mill intern vice presid besselaar one largest cro worldwid said dramat increas amount contract clinic trial
past coupl year twice number propos say dr mill
compani request part servic request full work add
measur much clinic trial cost highlight prof
richard peto clinic trial servic unit radcliff infirmari oxford carri signific trial peopl effect cholesterol lower drug
trial cost pound equal sponsor roch merck mrc
accord spokesman us pharmaceut manufactur associ clinic trial us cost dollar per patient six month period
us congress creat agenc health care polici research ahcpr comb vast databas record accumul hospit insur govern health programm sinc late
spend nearli dollar thi type research ahcpr cannot point singl case databas studi chang clinic practic comment prof peto
mani compani industri hope intern confer harmonis ich process save lot time money clinic trial
desir japanes regulatori agenc harmonis requir europ america
dr trevor jone research develop director well come say
repeat stabil data storag shelf life
difficulti clinic side still case repeat lot clinic work japan
mostli clinic relat scientist japan carri necessari phase iii trial add
dr jone say well come ha reorganis r meet global chang
new group set well come call euroclin prelud worldclin
ha staff spread geograph across europ
larg group franc group itali germani basic acquisit data thi ha done without incent tax relief three veri import advantag
dr pierr simon research develop director sanofi observ set high standard get compound full develop
look strength oral activ durat action toxicolog genotox
also make sure molecul metabolis man
drug ha clear bar even set high say dr simon
organis trial like anti thrombot clopidogrel thi real challeng add
need two year studi centr patient
far enrol patient far faster thought save six month
j anoth compani keep tight rein clinic trial prepar fujisawa dr hitoshi oyasu manag director research develop divis comment
like cut compound product pipelin clinic trial costli
look pre clinic data clinic advantag get kill
cut promis oral anti histamin onli last year add
compani believ ich make differ futur clinic trial one day progress seem difficult moment
tri reduc number clinician centr use trial
want focu investig reliabl deliv data time
past japanes group use clinic trial part market strategi case wa onli one patient per hospit
dr william scott senior vice presid exploratori drug discoveri bristol myer squibb say
save one year develop equival final year sale
big compound could dollar comment dr scott
even cost front save time worth hundr million dollar
problem hurdl get higher time add
regulatori process becom increasingli complex demand take fact trial use activ control compound compar new molecul old one
fact regulatori author ask clinic end point rather surrog marker
admittedli one counter trend area life threaten diseas avail therapi
get acceler approv use surrog marker
bm thi ddi gave patient gave patient taxol wa also given acceler approv
writer alan archer editor ft newslett pharmaceut busi news
select approach case studi schere plough research institut
us pharmaceut compani impend health care reform promis era increas cost contain price control
accord dr robert spiegel senior vice presid clinic research schere plough research institut market new drug never subsid believ alway market veri profit market drug compani develop novel product sati fy unmet need import therapeut area say
schere plough spent usdollar research develop invest expect increas dollar thi year
despit continu commit r fund schere plough admit cost driven market ha trigger chang approach
new world forc us even adapt research develop process say dr spiegel
schere plough thi adapt ha evolutionari
three year ago compani set pharmaceut econom unit design assess econom cost qualiti life benefit potenti new drug earliest possibl stage
evalu exactli schere plough expect bring market product fulli develop promin part core r process say dr spiegel
combin thi select approach r knowledg way discov breakthrough product drug compani inevit expos greater risk
thi mean manufactur increasingli dare decid compound back
onli go alzheim drug winner pharmaceut industri nice pot gold end process lot loser along way
willing conduct research high risk area guarante commerci success
raul cesan presid schere laboratori suggest
want develop someth uniqu yet may end someth margin improv
develop compound may offer onli slightli better safeti profil product al readi market luxuri research base drug compani longer afford
certain case margin improv give system exactli politician govern offici want
lower price becaus onc two three four product price collaps immedi argu raul cesan
research schere plough cover six main therapeut area
accord dr spiegel secret compani r success lie balanc discoveri area
support research quit comfort scientif field high risk area great potenti yield
time brand new area regulatori environ clinic develop environ also unknown
area high potenti success worth take risk
howev incent take risk could soon disappear price control propos health care reform approv propos sever review ultim price drug even breakthrough product give disincent much risk money would put type activ warn dr spiegel
ani case believ current market forc take care price control within drug industri
annual report publish last week schere plough announc held averag us net prescript drug price increas rate increas consum price index cpi expect price rise increas cpi
price moder dramat comment raul cesan
individu compani may suffer loss appetit r risk take us drug industri whole maintain commit r teamwork
joint ventur allianc univers research depart smaller biotechnolog compani establish pharmaceut compani show pool resourc drug compani continu search innov product
futur dr spiegel predict incent form allianc research area spread bet certainli concept embrac
annual report schere plough say per cent research dollar target biotechnolog
anoth form allianc ha seen us drug compani tap market manag care
last year merck co acquir health mainten organis medco contain servic dollar bn move wide regard attempt protect market share
effect acquisit chang merck mission research base pharmaceut compani jor player health care market
redefinit compani busi strategi anticip schere plough
ensur long term surviv beyond health care reform compani believ continu invest r pipelin essenti
find veri success ful drug eventu otherwis cannot surviv
research move sharper focu therapeut categori
grow th world pharmaceut market continu deceler research develop manag forc focus way direct compani r effort
think r spend slow say dr roy vagelo chairman chief execut merck
last year r ha grown per cent year
group respond new environ reduc number therapeut categori explor
admittedli giant group continu cover area
dr edward scolnick presid merck research laboratori say
compani without benefit r budget dollar bn year peopl work discoveri forc concentr effort
lead edg area research focus say mr lode wijk de vink presid chief oper offic warner lambert
soon talk burn rate pharmaceut compani still look area
choos therapeut area investig far easi hardest decis make area explor say dr william scott senior vice presid exploratori drug discoveri research bristol myer squibb
like kid go candi store credit card
mani r director continu duck difficult decis
although claim focus befor area continu explor cover human diseas
r director whose research look inflammatori diseas cover diseas divers asthm rheumatoid arthriti inflammatori bowel syndrom
choos area cover larg number criteria adopt compani
import probabl medic need biolog scienc accord dr scolnick biolog understand basic physiolog diseas mechan
find project right combin scientif understand medic need set work
dr takao tanakaya execut director drug discoveri divis fujisawa agre
although alzheim look interest becaus huge potenti market steer clear dementia becaus understand go
mean difficult develop anyth realli innov
compani also tri match unmet need expertis
schere plough manag onli work area match compani strength group ha suffici critic mass make differ accord dr robert spiegel senior vice presid clinic research
demand new treatment diseas elderli osteoporosi alzheim ha attract mani compani
dr teruhisa noguchi execut vice presid r yamanouchi explain
decid concentr cardiovascular gastro intestin central nervou system diseas well endocrinolog diabet bone disord
link age popul real problem japan
danger focus onli untreat unexplor area
group see need balanc risk differ therapeut categori
discoveri area quit comfort invest money patienc product come
high risk area scientif excit could great potenti yield hit right
problem new area realli difficult say dr spiegel
brand new field regulatori clinic environ unknown
park davi cognex approv nobodi knew sort efficaci fda want
number compani cut number therapeut area mean ful way
smith kline beecham exit gastro intestin diseas month ago wa area virtual creat predecessor smith kline french wa probabl dramat
howev well come ha also move tropic diseas dr trevor jone director research develop medic say group stop develop new anaesthet onc ha complet present gener product
dr pierr simon r director elf sanofi explain hi compani decis concentr onli three area
seven year ago sanofi wa present area research
told chairman wa stupid effect becaus develop becom sophist expens
dr leon rosenberg presid bristol myer squibb pharmaceut research institut say
scale back cardiovascular oncolog veri jor posit dermatolog
also stake futur immunolog area central nervou system diseas diagnost cannot lead
bright light shine everi thing concentr area leader greatest strength
onc therapeut area chosen r director next difficulti decid mani compound compet limit develop resourc select
last onli pursu new therapi produc clear medic benefit
onli develop distinct advantag say dr paul herrl head research sandoz
much scrutini use qualiti drug develop agre dr robert spiegel senior vice presid clinic research schere plough
look market bear product onli minor improv
medicin add valu otherwis prepar spend time money say sir richard syke chief execut glax
uniqu discoveri otherwis end sell gener drug
dr simon add recent cut beta blocker h antagonist hi pipelin even though safe effect made sens becaus littl better exist therapi
similarli rhone poulenc rorer last year cut safe effect ht antagonist similar glax highli success ful zofran becaus wa better exist compound accord mr robert cawthorn chief execut
group abandon even promis innov project howev
use biochem screen come interest compound fit exactli area want work
came good asthm drug intent get asthm
good clinic trial show good sell quickli
r director agre far easier develop good qualiti drug poor one
dr masaji ohno manag director r eisai agre
chairman mr yuji naito ask us find compound good develop themselv
set high standard get compound develop
look strength oral activ durat action toxicolog genotox
also make sure molecul metabolis man
drug ha clear bar even set high
product cost also import issu accord dr herrl
look complic molecul mani step take synthesis
cost complex manufactur becom much import say
dr stephen carter senior vice presid worldwid clinic research develop bristol myer squibb agre
go take chemic step produc compound might need chemist full time work year gener enough clinic trial
potenti market drug also clearli import
dr noguchi yamanouchi say hi compani ha set target minimum annual sale bn dollar drug move develop
one consequ new cost consciou environ decis futur molecul made much earlier befor
recent discontinu coupl compound earlier time would continu see happen
today luxuri say dr spiegel schere plough
howev although compani pay lip servic ride drive toward innov r director admit need balanc portfolio risk
japan low risk low reward compound call surviv drug accord dr masaji ohno manag director r eisai
let honest thi agre dr carter bristol myer squibb
go high risk high reward blockbust go home run
need balanc across franchis across risk
dollar product old franchis valuabl dollar product new area
howev dr spiegel admit set find someth excit sometim onli come drug offer margin improv
import area littl stress r director publicli line extens
call process evergreen say dr john niblack presid pfizer central research
dr carter bristol myer squibb agre
line extens help qualiti life gener increas exclus compani
besid develop line extens easier develop new compound becaus safeti al readi proven show efficaci
